[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 326
1. Beer S, Bellovin DI, Lee JS, Komatsubara K, Wang LS, Koh H, Börner K, Storm TA, Davis CR, Kay MA, Felsher DW, Grimm D: Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in adult mice. Mol Ther; 2010 Jan;18(1):161-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in adult mice.
  • As expected, the shRNAs silenced hepatic p53 and accelerated liver tumorigenesis when MYC was concurrently expressed.
  • In MYC-expressing transgenic mice, the marginal shRNA-induced liver injury sufficed to further stimulate hepatocellular division that was in turn associated with markedly increased expression of the mitotic cyclin B1.
  • Hence, even at low doses, shRNAs can cause low-level hepatoxicity that can facilitate the ability of the MYC oncogene to induce liver tumorigenesis.
  • [MeSH-major] Carcinoma, Hepatocellular / chemically induced. Genes, myc / physiology. Liver Neoplasms, Experimental / chemically induced. RNA, Small Interfering / adverse effects

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 2001 Mar;33(3):738-50 [11230756.001]
  • [Cites] Annu Rev Cell Dev Biol. 2000;16:653-99 [11031250.001]
  • [Cites] Gene Ther. 2001 Aug;8(16):1248-54 [11509958.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6487-93 [11522645.001]
  • [Cites] Adv Cancer Res. 2002;84:81-154 [11885563.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6274-9 [11983916.001]
  • [Cites] Semin Liver Dis. 2002;22(2):137-44 [12016545.001]
  • [Cites] Nat Genet. 2002 Aug;31(4):339-46 [12149612.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):764-76 [12360279.001]
  • [Cites] Nature. 2003 Jan 16;421(6920):290-4 [12529648.001]
  • [Cites] Curr Gene Ther. 2003 Aug;3(4):281-304 [12871018.001]
  • [Cites] Front Biosci. 1998 Feb 15;3:d250-68 [9468463.001]
  • [Cites] Nature. 2004 Oct 28;431(7012):1112-7 [15475948.001]
  • [Cites] Pharmacol Ther. 1989;43(1):139-54 [2675128.001]
  • [Cites] Cell. 1989 Dec 22;59(6):1145-56 [2598264.001]
  • [Cites] Cancer Res. 1990 Jun 1;50(11):3400-7 [1692259.001]
  • [Cites] Cell. 1993 Nov 5;75(3):451-62 [8106172.001]
  • [Cites] Am J Pathol. 1994 Nov;145(5):1237-45 [7977654.001]
  • [Cites] Hepatology. 1995 Oct;22(4 Pt 1):1316-25 [7557887.001]
  • [Cites] J Virol. 1996 Jul;70(7):4646-54 [8676491.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10933-8 [8855286.001]
  • [Cites] J Biol Chem. 1998 Jun 19;273(25):15639-45 [9624157.001]
  • [Cites] Mol Cell Biol. 1999 Jan;19(1):1-11 [9858526.001]
  • [Cites] Carcinogenesis. 1999 Jan;20(1):41-9 [9934848.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3940-4 [10097142.001]
  • [Cites] Oncogene. 1999 May 13;18(19):2934-41 [10378690.001]
  • [Cites] Mol Cell. 1999 Aug;4(2):199-207 [10488335.001]
  • [Cites] Semin Liver Dis. 1999;19(3):243-52 [10518304.001]
  • [Cites] PLoS Biol. 2004 Nov;2(11):e332 [15455033.001]
  • [Cites] J Virol. 2005 Jan;79(1):214-24 [15596817.001]
  • [Cites] Methods Enzymol. 2005;392:381-405 [15644194.001]
  • [Cites] Toxicol Pathol. 2005;33(1):181-4 [15805070.001]
  • [Cites] Cancer Biol Ther. 2004 Oct;3(10):942-4 [15611633.001]
  • [Cites] Gene Ther. 2006 Mar;13(6):563-75 [16453009.001]
  • [Cites] Nature. 2006 May 25;441(7092):537-41 [16724069.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7390-4 [16885332.001]
  • [Cites] Nat Methods. 2006 Sep;3(9):689-95 [16929313.001]
  • [Cites] Genome Biol. 2006;7(8):231 [16942630.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):14917-22 [17848523.001]
  • [Cites] Nat Genet. 2008 Jan;40(1):43-50 [18066065.001]
  • [Cites] J Virol. 2008 Jun;82(12):5887-911 [18400866.001]
  • [Cites] J Biol Chem. 2008 Jul 11;283(28):19184-91 [18456653.001]
  • [Cites] J Biol Chem. 2008 Aug 8;283(32):22186-92 [18524776.001]
  • [Cites] Mol Ther. 2008 Sep;16(9):1630-6 [18665161.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Oct;9(10):810-5 [18698328.001]
  • [Cites] Cell. 2009 Jun 12;137(6):1005-17 [19524505.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2229-34 [10688915.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2000;40:42-65 [10836127.001]
  • [Cites] Mol Carcinog. 2000 Jul;28(3):168-73 [10942533.001]
  • [Cites] J Virol. 2001 Aug;75(15):6969-76 [11435577.001]
  • (PMID = 19844192.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01-CA03423; United States / NCI NIH HHS / CA / R01-CA89305; United States / NIDDK NIH HHS / DK / DK078424; United States / NCI NIH HHS / CA / F32-CA132312; United States / NCI NIH HHS / CA / R01 CA089305; United States / NCI NIH HHS / CA / F32 CA132312; United States / NIDDK NIH HHS / DK / R01 DK078424; United States / NCI NIH HHS / CA / P50-CA114747; United States / NCI NIH HHS / CA / R01 CA105102; United States / NCI NIH HHS / CA / R01-CA105102; United States / NCI NIH HHS / CA / P50 CA114747
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Small Interfering
  • [Other-IDs] NLM/ PMC2839214
  •  go-up   go-down


2. Ji SP, Li Q, Dong H: Therapy and prognostic features of primary clear cell carcinoma of the liver. World J Gastroenterol; 2010 Feb 14;16(6):764-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy and prognostic features of primary clear cell carcinoma of the liver.
  • AIM: To clarify the therapeutic strategies and prognosis factors of primary clear cell carcinoma of the liver (PCCCL).
  • The Kaplan-Meier method showed that capsule formation, preoperative liver function, hepatitis C virus infection, large vascular invasion and multiple tumor occurrences were related to disease-free survival.
  • Cox regression analysis showed that the clear cell ratio, capsule formation, preoperative liver function and large vascular invasion were independent risk factors for overall survival.
  • Clear cell ratio, capsule formation, preoperative liver function, and vascular invasion were independent risk factors for prognosis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / surgery. Leucovorin / therapeutic use. Liver Neoplasms / drug therapy. Liver Neoplasms / surgery. Tegafur / therapeutic use
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / therapeutic use. Combined Modality Therapy. Female. Hepatectomy. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):177-82 [10680884.001]
  • [Cites] World J Gastroenterol. 2008 Mar 21;14(11):1652-6 [18350595.001]
  • [Cites] Histopathology. 2001 Mar;38(3):225-31 [11260303.001]
  • [Cites] Kaohsiung J Med Sci. 2004 Feb;20(2):78-82 [15481555.001]
  • [Cites] Cancer. 1979 Nov;44(5):1677-83 [227575.001]
  • [Cites] Pathologica. 1994 Jun;86(3):307-10 [7808805.001]
  • [Cites] Pathol Int. 1996 Jul;46(7):503-9 [8870006.001]
  • [Cites] Dig Dis Sci. 1998 Jan;43(1):33-8 [9508531.001]
  • [Cites] Oncogene. 1999 Jan 7;18(1):181-7 [9926933.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2005;12(2):155-8 [15868082.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2005 May;4(2):306-7 [15908336.001]
  • [Cites] World J Surg. 2006 Mar;30(3):439-45 [16479331.001]
  • [Cites] Hepatogastroenterology. 2006 Jan-Feb;53(67):128-32 [16506391.001]
  • [Cites] Oncogene. 2006 Jun 26;25(27):3866-84 [16799628.001]
  • [Cites] World J Surg. 2007 Jun;31(6):1243-8 [17440771.001]
  • [Cites] World J Gastroenterol. 2008 Jan 7;14(1):129-31 [18176975.001]
  • [Cites] Liver Int. 2008 Feb;28(2):175-88 [18251977.001]
  • [Cites] Mod Pathol. 2000 Aug;13(8):874-81 [10955454.001]
  • (PMID = 20135727.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 1548R74NSZ / Tegafur; Q573I9DVLP / Leucovorin
  • [Other-IDs] NLM/ PMC2817067
  •  go-up   go-down


3. Liu ZZ, Huang WY, Lin JS, Li XS, Lan X, Cai XK, Liang KH, Zhou HJ: Cell survival curve for primary hepatic carcinoma cells and relationship between SF(2) of hepatic carcinoma cells and radiosensitivity. World J Gastroenterol; 2005 Nov 28;11(44):7040-3
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell survival curve for primary hepatic carcinoma cells and relationship between SF(2) of hepatic carcinoma cells and radiosensitivity.
  • AIM: To establish the cell survival curve for primary hepatic carcinoma cells and to study the relationship between SF(2) of primary hepatic carcinoma cells and radiosensitivity.
  • METHODS: Hepatic carcinoma cells were cultured in vitro using 39 samples of hepatic carcinoma at stages II-IV.
  • After these cells were radiated with different dosages, the cell survival ratio and SF(2) were calculated by clonogenic assay and SF(2) model respectively.
  • After X-ray radiation of the fifth generation cells with 0, 2, 4, 6, 8 Gy, the cell survival rate was 41%, 36.5%, 31.0%, 26.8%, and 19%, respectively.
  • There was a negative correlation between cell survival and irradiation dosage (r = -0.973, P<0.05).
  • SF(2) ranged 0.28-0.78 and correlated with the clinical stage and pathological grade of hepatic carcinoma (P<0.05).
  • CONCLUSION: SF(2) correlates with the clinical stage and pathological grade of hepatic carcinoma and is a marker for predicting the radiosensitivity of hepatic carcinomas.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / radiotherapy. Cell Survival. Liver Neoplasms / pathology. Liver Neoplasms / radiotherapy. Radiation Tolerance
  • [MeSH-minor] Adult. Aged. Animals. Cell Culture Techniques. Dose-Response Relationship, Radiation. Humans. Middle Aged. Neoplasm Staging. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437614.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4717052
  •  go-up   go-down


Advertisement
4. Tsai S, Gurakar A, Anders R, Lam-Himlin D, Boitnott J, Pawlik TM: Management of large hepatocellular carcinoma in adult patients with Alagille syndrome: a case report and review of literature. Dig Dis Sci; 2010 Nov;55(11):3052-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of large hepatocellular carcinoma in adult patients with Alagille syndrome: a case report and review of literature.
  • BACKGROUND: Alagille syndrome is a multi-system developmental disorder associated with paucity of interlobular bile ducts and cholestasis, rarely associated with hepatocellular carcinoma.
  • As such, we herein review the modern management of a large hepatocellular carcinoma in an adult patient with Alagille syndrome and review the literature of adult Alagille patients with hepatocellular carcinoma.
  • CASE PRESENTATION: A 29-year-old woman with a history of Alagille syndrome was referred with biopsy-proven 12 × 8 cm hepatocellular carcinoma replacing her right liver.
  • Biopsy of the contralateral liver demonstrated findings consistent with Alagille syndrome, but no underlying cirrhosis.
  • CT volumetrics demonstrated a future liver remnant of 40%.
  • [MeSH-major] Alagille Syndrome / epidemiology. Carcinoma, Hepatocellular / epidemiology. Carcinoma, Hepatocellular / surgery. Hepatectomy / methods. Liver Neoplasms / epidemiology. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Comorbidity. Female. Humans. Magnetic Resonance Imaging. Tomography, X-Ray Computed


5. Nan KJ, Ruan ZP, Jing Z, Qin HX, Wang HY, Guo H, Xu R: Expression of fragile histidine triad in primary hepatocellular carcinoma and its relation with cell proliferation and apoptosis. World J Gastroenterol; 2005 Jan 14;11(2):228-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of fragile histidine triad in primary hepatocellular carcinoma and its relation with cell proliferation and apoptosis.
  • AIM: To evaluate the expression of fragile histidine triad (FHIT) gene protein, product of a candidate tumor suppressor, and to investigate the relationship between FHIT, cell apoptosis and proliferation, and pathological features of primary hepatocellular carcinoma (HCC).
  • METHODS: Forty-seven HCC and ten normal liver specimens were collected during surgical operation between 2001 and 2003.
  • FHIT and proliferating cell nuclear antigen (PCNA) expression were detected by immunohistochemistry, and apoptotic level was evaluated by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay on the tissue sections.
  • RESULTS: All normal liver tissues showed a strong expression of FHIT, whereas 28 of 47 (59.6%) carcinomas showed a significant loss or absence of FHIT expression (P = 0.001).
  • Apoptotic incidence in advanced TNM stage carcinoma and those with positive FHIT expression was higher than that in early stage carcinoma (P = 0.030) and in those with negative FHIT expression (P = 0.044) respectively.
  • The proliferating potential of hepatocellular carcinoma was associated with FHIT expression (P = 0.016) and the aggressive feature (P = 0.019).
  • [MeSH-major] Acid Anhydride Hydrolases / genetics. Apoptosis / genetics. Carcinoma, Hepatocellular / genetics. Carcinoma, Hepatocellular / pathology. Cell Division / genetics. Genes, Tumor Suppressor. Histidine / genetics. Liver Neoplasms / genetics. Liver Neoplasms / pathology. Neoplasm Proteins / genetics
  • [MeSH-minor] Adult. Female. Humans. Liver / physiology. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Reference Values

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. (L)-HISTIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15633221.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; 4QD397987E / Histidine; EC 3.6.- / Acid Anhydride Hydrolases
  • [Other-IDs] NLM/ PMC4205407
  •  go-up   go-down


6. Nan KJ, Guo H, Ruan ZP, Jing Z, Liu SX: Expression of p57(kip2) and its relationship with clinicopathology, PCNA and p53 in primary hepatocellular carcinoma. World J Gastroenterol; 2005 Feb 28;11(8):1237-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p57(kip2) and its relationship with clinicopathology, PCNA and p53 in primary hepatocellular carcinoma.
  • AIM: To investigate the expression of p57(kip2) and its relationship with clinicopathology, PCNA and p53 in primary hepatocellular carcinoma (HCC).
  • METHODS: Expression of p57(kip2), PCNA and p53 in tumor tissues from 32 patients with HCC and 10 liver tissues of normal persons was detected with Elivision immunohistochemical technique.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. Nuclear Proteins / metabolism. Proliferating Cell Nuclear Antigen / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Aged. Apoptosis / physiology. Cyclin-Dependent Kinase Inhibitor p57. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15754413.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CDKN1C protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p57; 0 / Nuclear Proteins; 0 / Proliferating Cell Nuclear Antigen; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC4250722
  •  go-up   go-down


7. Lee HL, Liu YY, Yeh CN, Chiang KC, Chen TC, Jan YY: Primary squamous cell carcinoma of the liver: a successful surgically treated case. World J Gastroenterol; 2006 Sep 7;12(33):5419-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary squamous cell carcinoma of the liver: a successful surgically treated case.
  • Primary squamous cell carcinoma (SCC) of the liver is rare.
  • Primary SCC of the liver has been reported to be associated with hepatic teratoma, hepatic cyst, or hepatolithiasis.
  • Complete remission of poorly differentiated SCC of the liver could be achieved by systemic chemotherapy followed by surgery or remarkably respond to hepatic arterial injection of low dose chemotherapeutic drugs.
  • Here we report the first case of primary SCC of the liver presenting as a solid tumor and receiving successful hepatic resection with 9-mo disease free survival.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / surgery. Liver Neoplasms / diagnosis. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Disease-Free Survival. Humans. Liver / pathology. Liver / ultrasonography. Male. Remission Induction. Treatment Outcome. Ultrasonography

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Int. 2003 Feb;53(2):90-7 [12588436.001]
  • [Cites] Kurume Med J. 2003;50(1-2):71-5 [12971268.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2004 Oct;16(10):1051-6 [15371931.001]
  • [Cites] Cancer. 1976 Nov;38(5):2002-5 [991114.001]
  • [Cites] Gut. 1990 Nov;31(11):1333-4 [2253922.001]
  • [Cites] Cell Prolif. 2005 Dec;38(6):407-21 [16300653.001]
  • [Cites] HPB Surg. 1992 Apr;5(3):203-8 [1510892.001]
  • [Cites] J Surg Oncol. 1994 Nov;57(3):210-2 [7967614.001]
  • [Cites] Acta Cytol. 1996 Mar-Apr;40(2):339-45 [8629424.001]
  • [Cites] Tumori. 2005 Jan-Feb;91(1):71-2 [15850008.001]
  • [Cites] Aust N Z J Surg. 1991 Sep;61(9):720-2 [1877947.001]
  • (PMID = 16981283.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4088220
  •  go-up   go-down


8. Salguero FJ, Richard A, Gough J, Long A, Weyer U, Cooley WA, Chambers MA, Lesellier S: Pelioid hepatocellular carcinoma in an adult Eurasian badger (Meles meles). J Comp Pathol; 2010 Feb-Apr;142(2-3):208-12
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pelioid hepatocellular carcinoma in an adult Eurasian badger (Meles meles).
  • A mass was identified within the left lateral lobe of the liver of a 10-year-old Eurasian badger (Meles meles).
  • The histological appearance was consistent with hepatocellular carcinoma (HCC).
  • [MeSH-major] Carcinoma, Hepatocellular / veterinary. Liver / pathology. Liver Neoplasms / veterinary. Mustelidae

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Crown Copyright 2009. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19683720.001).
  • [ISSN] 1532-3129
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Hervieu V, Lombard-Bohas C, Dumortier J, Boillot O, Scoazec JY: Primary acinar cell carcinoma of the liver. Virchows Arch; 2008 Mar;452(3):337-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary acinar cell carcinoma of the liver.
  • We report a case of acinar cell carcinoma primary to the liver.
  • The tumor was diagnosed in a 35-year-old woman complaining of abdominal pain and asthenia; serum alpha-fetoprotein (AFP) levels were increased at 6,000 IU/mL; imaging studies showed a hypervascular mass located in the left lobe of the liver.
  • The final diagnosis, based on histological, immunohistochemical, and ultrastructural arguments, was extra-pancreatic acinar cell carcinoma, primary to the liver.
  • This unusual lesion is likely to be the result of an abnormal differentiation pathway involving a transformed multipotential progenitor cell.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Liver / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Immunohistochemistry. Treatment Outcome. alpha 1-Antitrypsin / analysis. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18193278.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / alpha 1-Antitrypsin; 0 / alpha-Fetoproteins
  •  go-up   go-down


10. Wilson FD, Fitzgerald SD, Kiupel M, Walker RL, Williams CB, Todd DJ: Occurrence of hepatocellular carcinoma in an adult male Nile lechwe (Kobus megaceros). J Zoo Wildl Med; 2007 Jun;38(2):329-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occurrence of hepatocellular carcinoma in an adult male Nile lechwe (Kobus megaceros).
  • The liver was grossly enlarged and contained a smooth-surfaced nodular mass that occupied the majority of the right lobe of the liver.
  • The mass had a liver-like appearance exhibiting a tan-red coloration but having a soft consistency.
  • To our knowledge, this is the first report in the scientific literature of a naturally occurring case of hepatocellular carcinoma in a Nile lechwe or in any antelope species.
  • [MeSH-major] Antelopes. Carcinoma, Hepatocellular / veterinary. Liver Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17679519.001).
  • [ISSN] 1042-7260
  • [Journal-full-title] Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians
  • [ISO-abbreviation] J. Zoo Wildl. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Balta Z, Sauerbruch T, Hirner A, Büttner R, Fischer HP: [Primary neuroendocrine carcinoma of the liver. From carcinoid tumor to small-cell hepatic carcinoma: case reports and review of the literature]. Pathologe; 2008 Feb;29(1):53-60
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary neuroendocrine carcinoma of the liver. From carcinoid tumor to small-cell hepatic carcinoma: case reports and review of the literature].
  • Primary hepatic neuroendocrine tumors are rare neoplasms.
  • While primary hepatic carcinoid tumors (PHCT) are well-differentiated tumors, primary hepatic small-cell carcinomas (PHSCC) represent the poorly differentiated end of the spectrum of neuroendocrine carcinomas.
  • The second patient suffered from small-cell carcinoma of the liver.
  • There were no risk factors for a hepatocellular carcinoma.
  • An extensive preoperative and postoperative diagnostic investigation could rule out an extrahepatic primary site.
  • After neoadjuvant cytostatic treatment the carcinoma was completely extirpated and 18 months after treatment the patient is healthy.PHCT and PHSCC have to be clearly separated from hepatocellular and cholangiocellular carcinomas.
  • Exclusion of an extrahepatic primary site requires an accurate and synoptic analysis of clinical, radiologic and pathologic findings.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoid Tumor / pathology. Carcinoma / drug therapy. Carcinoma / pathology. Carcinoma, Neuroendocrine / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Carboplatin / administration & dosage. Cell Differentiation. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Rectal Neoplasms / pathology. Risk Factors. Treatment Outcome


12. Otegbayo JA, Yakubu A, Akere A, Igetei R, Aje AO: Quality of life among primary liver cell carcinoma patients in Ibadan, Nigeria. Afr J Med Med Sci; 2005 Mar;34(1):51-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life among primary liver cell carcinoma patients in Ibadan, Nigeria.
  • A descriptive prospective study was conducted to evaluate the quality of life of patients with primary liver cell carcinoma at the University College Hospital, Ibadan, Nigeria.
  • [MeSH-major] Carcinoma / psychology. Liver Neoplasms / psychology. Quality of Life. Sickness Impact Profile
  • [MeSH-minor] Adult. Aged. Female. Hospitals, University. Humans. Male. Middle Aged. Nigeria. Patient Satisfaction. Prognosis. Prospective Studies. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15971554.001).
  • [ISSN] 0309-3913
  • [Journal-full-title] African journal of medicine and medical sciences
  • [ISO-abbreviation] Afr J Med Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


13. Ye XP, Li LQ, Peng T, Xiao KY, Su ZX, Shang LM, Su M, Xu BH: [Diagnosis and treatment of primary clear cell carcinoma of the liver]. Zhonghua Zhong Liu Za Zhi; 2010 Jan;32(1):64-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of primary clear cell carcinoma of the liver].
  • OBJECTIVE: To investigate the clinicopathological features, diagnosis, treatment and prognosis of primary clear cell carcinoma of the liver (PCCCL).
  • Liver cirrhosis was found in 75.0% of the patients.
  • CONCLUSION: The clinical characteristics of primary clear cell carcinoma of the liver are similar to that of common hepatocellular carcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Hepatectomy. Liver Neoplasms / pathology. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Hepatitis B. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Rate. alpha-Fetoproteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20211073.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


14. Lao XM, Zhang YQ, Jin X, Lin XJ, Guo RP, Li GH, Li JQ: Primary clear cell carcinoma of liver--clinicopathologic features and surgical results of 18 cases. Hepatogastroenterology; 2006 Jan-Feb;53(67):128-32
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary clear cell carcinoma of liver--clinicopathologic features and surgical results of 18 cases.
  • BACKGROUND/AIMS: Primary clear cell carcinoma of the liver (PCCCL) is a subgroup of hepatocellular carcinoma.
  • The differentiation degree ranged from grade 1 to 3, liver cirrhosis or/and chronic hepatitis was present in paratumorous tissues.
  • The clinical characteristics of the PCCCL are similar to those of conventional hepatocellular carcinoma.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / pathology. Liver Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16506391.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


15. Zhong XG, He S, Yin W, Deng JY, Chen B: [Tropism of adult liver stem cells toward hepatocellular carcinoma cells in vitro]. Zhonghua Gan Zang Bing Za Zhi; 2005 Sep;13(9):644-7
MedlinePlus Health Information. consumer health - Stem Cells.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tropism of adult liver stem cells toward hepatocellular carcinoma cells in vitro].
  • OBJECTIVE: To explore the biological behavior of adult liver stem cells in a co-cultured system of them with hepatocellular carcinoma (HCC) cells without direct contact between the two kinds of cells.
  • METHODS: WB-F344, a kind of rat adult liver stem cell, and rat embryonic fibroblasts (REF) from a primary culture were engineered to express enhanced green fluorescent protein (EGFP) by recombinant adenoviral-mediated methods.
  • After the HCC cells grew to 40%-60% confluence in the culture dish with a 10-mm cell-free area, a similar number of WB-EGFP and REF-EGFP were placed in the blank areas respectively.
  • Their appearance was found not only when WB-EGFP cells were seeded into the cell-free area at the center of the dish, but also when seeded into the blank area at the extreme edge of the plate.
  • CONCLUSIONS: The results mean that adult liver stem cells have a biological behavior of selective tropism toward HCC cells in vitro, and suggest a possibility of using migratory liver stem cells as a delivery vehicle for gene therapy for HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver / cytology. Liver Neoplasms / pathology. Stem Cells / cytology

  • Genetic Alliance. consumer health - Hepatocellular carcinoma, adult.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16174449.001).
  • [ISSN] 1007-3418
  • [Journal-full-title] Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  • [ISO-abbreviation] Zhonghua Gan Zang Bing Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


16. Achneck HE, Pradhan SK, Kavic SM, Longo WE: Primary signet-ring cell carcinoma mimicking segmental Crohn's colitis. Dig Liver Dis; 2005 Jul;37(7):537-41
Hazardous Substances Data Bank. Barium sulfate .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary signet-ring cell carcinoma mimicking segmental Crohn's colitis.
  • Primary signet-ring cell carcinoma of the colon is a rare entity with a dismal prognosis, mainly due to a delay in diagnosis.
  • A subsequent biopsy revealed poorly differentiated signet-ring cell carcinoma of the colon.
  • She was treated surgically with a left hemi-colectomy and primary repair.
  • A high degree of suspicion is necessary to correctly diagnose these, often young, patients with primary signet-ring cell carcinoma early and have a positive impact on survival.
  • The literature on primary signet-ring cell carcinoma is reviewed.
  • [MeSH-major] Carcinoma, Signet Ring Cell / diagnosis. Colonic Neoplasms / diagnosis. Crohn Disease / diagnosis
  • [MeSH-minor] Abdominal Pain / etiology. Adult. Barium Sulfate. Colectomy. Colonoscopy. Enema. Female. Humans. Recurrence

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15975543.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 25BB7EKE2E / Barium Sulfate
  •  go-up   go-down


17. Burri E, Steuerwald M, Cathomas G, Mentha G, Majno P, Rubbia-Brandt L, Meier R: Hepatocellular carcinoma in a liver-cell adenoma within a non-cirrhotic liver. Eur J Gastroenterol Hepatol; 2006 Apr;18(4):437-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma in a liver-cell adenoma within a non-cirrhotic liver.
  • Liver-cell adenomas are benign lesions of the liver occurring predominantly in young women.
  • Hepatocellular carcinomas in most of the cases arise in a cirrhotic liver during the fifth or sixth decade.
  • Tests for chronic liver diseases were negative.
  • The tumour was surgically removed and a hepatocellular carcinoma arising within a liver-cell adenoma in a non-cirrhotic liver was found.
  • Malignant transformation of liver-cell adenoma has only been reported in a few case reports.
  • [MeSH-major] Adenoma, Liver Cell / pathology. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Adult. Female. Humans

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16538118.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 42
  •  go-up   go-down


18. Shah S, Gupta S, Shet T, Maheshwari A, Wuntkal R, Mohandas KM: Metastatic clear cell variant of hepatocellular carcinoma with an occult hepatic primary. Hepatobiliary Pancreat Dis Int; 2005 May;4(2):306-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic clear cell variant of hepatocellular carcinoma with an occult hepatic primary.
  • Metastatic clear cell carcinomas are commonly seen in the kidney and lung.
  • Clear cell variant of hepatocellular carcinoma is an uncommon tumour.
  • In this unusual case of metastatic clear cell carcinoma presenting as Sister Mary Joseph's nodule, no primary evidence was observed radiologically in the liver, but the level of alfa fetoprotein was markedly elevated.
  • Metastatic clear cell carcinoma of the liver with an occult hepatic primary was diagnosed by immunohistochemical profile of the tumour.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Neoplasms, Second Primary / pathology. alpha-Fetoproteins / analysis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Biopsy, Needle. Follow-Up Studies. Humans. Immunohistochemistry. Male. Neoplasm Staging. Risk Assessment. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15908336.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins
  •  go-up   go-down


19. Zhan XK, Sun YK, Zhang W, Wang JW: [Clinical analysis of 81 cases with primary small cell carcinoma of the esophagus]. Zhonghua Zhong Liu Za Zhi; 2008 Dec;30(12):926-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 81 cases with primary small cell carcinoma of the esophagus].
  • OBJECTIVE: To evaluate the clinical characteristics, treatment and prognostic factors in patients with primary small cell carcinoma (SmCC) of the esophagus.
  • CONCLUSION: Esophageal small cell carcinoma is a rare but highly aggressive malignant tumor.
  • [MeSH-major] Carcinoma, Small Cell / therapy. Esophageal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / therapeutic use. Combined Modality Therapy. Esophagectomy. Etoposide / therapeutic use. Female. Follow-Up Studies. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Neoplastic Cells, Circulating. Proportional Hazards Models. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173995.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; JET protocol
  •  go-up   go-down


20. Nagao Y, Sata M: High incidence of multiple primary carcinomas in HCV-infected patients with oral squamous cell carcinoma. Med Sci Monit; 2009 Sep;15(9):CR453-9
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High incidence of multiple primary carcinomas in HCV-infected patients with oral squamous cell carcinoma.
  • We investigated the association among oral squamous cell carcinoma (OSCC), multiple primary cancers (MPCs), insulin resistance and HCV infection.
  • MATERIAL/METHODS: Upper gastrointestinal tract examination and determination of the presence of HCV infection were routinely done for 60 primary OSCC patients.
  • In HCV-infected cases, 10 MPCs with patients, hepatocellular carcinoma (HCC) was the most common outcome (5 cases), whereas gastric cancer was the most common outcome (6 cases) in non-HCV-infected 11 MPCs.
  • CONCLUSIONS: HCV infection was strongly associated with the occurrence of MPCs as well as primary OSCC.
  • In patients with HCV infection, it is important to clinically examine organs other than the liver.
  • [MeSH-major] Carcinoma, Squamous Cell. Hepacivirus / metabolism. Hepatitis C. Mouth Neoplasms. Neoplasms, Multiple Primary / etiology. Neoplasms, Multiple Primary / virology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Insulin Resistance. Male. Middle Aged. Multivariate Analysis. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19721396.001).
  • [ISSN] 1643-3750
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  •  go-up   go-down


21. Schiel KA: An etiologic model proposing that sporadic adult-onset carcinoma is extramedullary hematopoiesis. Med Hypotheses; 2006;67(1):93-109
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An etiologic model proposing that sporadic adult-onset carcinoma is extramedullary hematopoiesis.
  • This model proposes that primary carcinomatous tumors and almost all metastases are extramedullary hematopoietic tissue formed to compensate for reduced hematopoietic activity in the bone marrow.
  • Specific carcinoma morphologies are equated to stages in endochondral bone and marrow formation and, as such, cancer cell identity varies with morphology.
  • Tubular breast carcinoma, with its single layer of osteoblast-like carcinoma cells encircling small lumens and long branching tubules, is equated to the trabecular stage of marrow formation during which osteoblasts surround small pieces of calcified cartilage and begin secreting osteoid that will form the trabeculae.
  • Lobular carcinoma in situ consists of cancer cell clusters separated by narrow clear spaces that, under high magnification, appear vascular.
  • If this model is correct it necessitates a change in the treatment of carcinoma.
  • [MeSH-major] Carcinoma / etiology. Hematopoiesis, Extramedullary. Liver Neoplasms / etiology
  • [MeSH-minor] Adult. Bone Marrow Cells. Granulocytes / metabolism. Hematopoietic Stem Cells / cytology. Humans. Leukemia / metabolism. Models, Biological. Neoplasm Metastasis. Primary Myelofibrosis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16540257.001).
  • [ISSN] 0306-9877
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


22. Thelen A, Jonas S, Benckert C, Lopez-Hänninen E, Rudolph B, Neumann U, Neuhaus P: Liver resection for metastases from renal cell carcinoma. World J Surg; 2007 Apr;31(4):802-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver resection for metastases from renal cell carcinoma.
  • BACKGROUND: This study was conducted to evaluate the safety and efficacy of liver resection in patients with hepatic metastases from renal cell carcinoma and to identify selection criteria for patients suitable for resection.
  • METHODS: Between January 1988 and March 2006, 31 patients underwent liver resection for metastases from renal cell carcinoma.
  • In the univariate analysis, site of the primary tumor (P = 0.013), disease-free interval (P = 0.012), and resection margins (P = 0.008) showed significant influence on long-term survival.
  • In the multivariate analysis, only the resection margins were identified as an independent prognostic factor after liver resection.
  • CONCLUSIONS: Liver resection is effective and safe in the treatment of patients with hepatic metastases from renal cell carcinoma and offers the chance of long-term survival and cure.
  • Achieving a margin-negative resection is the most important criterion in the selection of suitable patients for liver resection.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Hepatectomy / methods. Kidney Neoplasms / pathology. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Multivariate Analysis. Postoperative Complications. Proportional Hazards Models. Retrospective Studies. Statistics, Nonparametric. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17354021.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Kinoshita S, Hirano A, Komine K, Kobayashi S, Kyoda S, Takeyama H, Uchida K, Morikawa T, Nagase J, Sakamoto G: Primary small-cell neuroendocrine carcinoma of the breast: report of a case. Surg Today; 2008;38(8):734-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary small-cell neuroendocrine carcinoma of the breast: report of a case.
  • Primary small-cell neuroendocrine carcinoma of the breast is a rare and aggressive neoplasm without an established treatment protocol because so few cases have been described.
  • We report a case of primary small-cell neuroendocrine carcinoma in a 31-year-old woman.
  • Core needle biopsy under ultrasonographic guidance revealed invasive carcinoma.
  • Definitive histopathological examination revealed primary small-cell neuroendocrine carcinoma.
  • Local and mediastinal recurrence with multiple liver metastases developed only 5 weeks after surgery.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Neuroendocrine / pathology. Carcinoma, Small Cell / pathology
  • [MeSH-minor] Adult. Biopsy, Needle. Diagnosis, Differential. Fatal Outcome. Female. Humans. Neoplasm Invasiveness. Ultrasonography, Mammary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18668318.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 24
  •  go-up   go-down


24. Soeda J, Yazaki M, Nakata T, Miwa S, Ikeda S, Hosoda W, Iijima M, Kobayashi K, Saheki T, Kojiro M, Miyagawa S: Primary liver carcinoma exhibiting dual hepatocellular-biliary epithelial differentiations associated with citrin deficiency: a case report. J Clin Gastroenterol; 2008 Aug;42(7):855-60
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary liver carcinoma exhibiting dual hepatocellular-biliary epithelial differentiations associated with citrin deficiency: a case report.
  • We report a 50-year-old male patient with primary liver carcinoma exhibiting dual hepatocellular and biliary epithelial differentiations associated with citrin deficiency (asymptomatic adult-onset type II citrullinemia, CTLN2).
  • Although so far 14 CTLN2 patients with hepatocellular carcinoma have been reported, this report describes a unique case of liver carcinoma showing the features of both hepatocellular and cholangiocellular carcinoma.
  • In addition to the clinical data of the 14 patients reported previously, the findings in our patient suggest that the citrin deficiency might be one of the key disorders causing hepatocellular carcinoma especially at younger ages and can also play an important role in hepatocarcinogenesis of the hepatic progenitor cells, which have the bipotential to differentiate into both hepatocytes and cholangiocytes.
  • [MeSH-major] Bile Duct Neoplasms. Bile Ducts, Intrahepatic. Carcinoma, Hepatocellular. Cholangiocarcinoma. Citrullinemia / complications. Liver Neoplasms
  • [MeSH-minor] Cell Differentiation. Hepatectomy. Humans. Liver / cytology. Liver / pathology. Liver Failure / etiology. Male. Middle Aged

  • Genetic Alliance. consumer health - Citrin Deficiency.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18385606.001).
  • [ISSN] 1539-2031
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


25. Chen B, Gao L, Xu GZ, Li SY, Huang XD, Yi JL: [Postoperative radiotherapy for primary intraosseous carcinoma of the jaws]. Zhonghua Zhong Liu Za Zhi; 2007 Jul;29(7):540-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Postoperative radiotherapy for primary intraosseous carcinoma of the jaws].
  • OBJECTIVE: To investigate the indication, location and dose of postoperative radiotherapy for primary intraosseous carcinoma (PIOC) of the jaws.
  • It seemed that surgery plus postoperative radiotherapy could not improve the survival of PIOC patients with involvement of adjacent soft-tissues or positive neck nodes or partial excision of primary tumor when compared with surgery alone, if the bias of selection in the patients for postoperative radiotherapy was neglected.
  • CONCLUSION: Postopreative radiotherapy may improve the survival for the patient with primary intraosseous carcinoma of the jaws.
  • Our suggestion is that postoperative radiotherapy should be applied to the patient with any of the following items: positive operative margin; tumor involvement of adjacent soft-tissues; positive neck nodes; partial excision of primary tumor.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Mandibular Neoplasms / radiotherapy. Maxillary Neoplasms / radiotherapy. Radiotherapy, High-Energy
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Liver Neoplasms / secondary. Lymph Node Excision. Lymphatic Metastasis. Male. Mandible / surgery. Maxilla / surgery. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Radiotherapy, Adjuvant. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18069638.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 8
  •  go-up   go-down


26. Song Y, Wang LH, He J, Wang JW: [Treatment and prognosis of primary esophageal small cell carcinoma: a report of 151 cases]. Ai Zheng; 2009 Mar;28(3):303-7
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment and prognosis of primary esophageal small cell carcinoma: a report of 151 cases].
  • BACKGROUND AND OBJECTIVE: The treatment and prognosis of primary esophageal small cell carcinoma (PESC), an uncommon esophageal malignant tumor, have seldom been reported.
  • [MeSH-major] Carcinoma, Small Cell / surgery. Esophageal Neoplasms / surgery. Esophagectomy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Neoplastic Cells, Circulating / pathology. Proportional Hazards Models. Radiotherapy, Adjuvant. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19619447.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


27. Fan ZH, Chen MH, Dai Y, Wang YB, Yan K, Wu W, Yang W, Yin SS: Evaluation of primary malignancies of the liver using contrast-enhanced sonography: correlation with pathology. AJR Am J Roentgenol; 2006 Jun;186(6):1512-9
Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of primary malignancies of the liver using contrast-enhanced sonography: correlation with pathology.
  • OBJECTIVE: Our purpose was to investigate the correlation of contrast-enhanced sonographic patterns with the histopathology of primary malignancies of the liver.
  • RESULTS: All 65 moderately to poorly differentiated hepatocellular carcinomas (HCCs) enhanced in the arterial phase, and 96.9% (63 lesions) of them quickly washed out in the portal venous phase.
  • Seventy-five percent of the clear cell carcinomas (12/16) enhanced in the arterial phase, 25% (4/16) did not enhance until the portal venous phase, and 31.3% (5/16) of the clear cell carcinomas washed out slowly during the late phase.
  • The enhancement and washout times of clear cell carcinomas were significantly different than those of moderately to poorly differentiated HCCs (p < 0.05).
  • CONCLUSION: Our study showed that the enhancement manifestations of primary malignancies of the liver are related to pathologic types and grades.
  • Contrast-enhanced sonograms may provide the histopathologic information for malignant tumors of the liver.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / ultrasonography. Contrast Media. Liver Neoplasms / pathology. Liver Neoplasms / ultrasonography. Phospholipids. Sulfur Hexafluoride
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16714638.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Phospholipids; 0 / contrast agent BR1; WS7LR3I1D6 / Sulfur Hexafluoride
  •  go-up   go-down


28. Lee KH, Ryu SB, Lee MC, Park CS, Juhng SW, Choi C: Primary large cell neuroendocrine carcinoma of the urinary bladder. Pathol Int; 2006 Nov;56(11):688-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary large cell neuroendocrine carcinoma of the urinary bladder.
  • Primary large cell neuroendocrine carcinomas (LCNEC) of the urinary bladder are rare.
  • Reported herein is a case of a primary, pure LCNEC occurring in a man.
  • Two months after the primary transurethral resection, significant regrowth of the remnant mass was noted on CT, and the patient underwent a partial cystectomy.
  • In spite of three cycles of chemotherapy, the patient developed multiple metastases in the lung and liver 10 months postoperatively.
  • [MeSH-major] Carcinoma, Large Cell / secondary. Carcinoma, Neuroendocrine / secondary. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Chemotherapy, Adjuvant. Combined Modality Therapy. Cystectomy. Hospice Care. Humans. Immunoenzyme Techniques. Male. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17040293.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


29. Liu YM, Qin H, Wang CB, Fang XH, Ma QY: [Comparision of different interventional therapies for primary liver cancer]. Zhonghua Zhong Liu Za Zhi; 2007 Mar;29(3):232-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparision of different interventional therapies for primary liver cancer].
  • OBJECTIVE: To investigate the efficacy of different interventional therapies for primary hepatic cell cancer (HCC).
  • The results of liver function, alpha-fetoprotein, imaging, color-ultrasonography and survival rate were reviewed.
  • The Child grade of liver function, color-ultrasonography and alpha-fetoprotein of TACE + RFA group, TACE and TAI were compared.
  • CONCLUSION: Compared with other modalities, transcatheter arterial chemoembolization (TACE) before or after hepatectomy is more effective than other interventional therapies for primary hepatocellular cancer, whereas, if combined with radiofrequency ablation (TAI), it is much more effective than TACE alone.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic / methods. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Catheter Ablation. Combined Modality Therapy. Female. Follow-Up Studies. Hepatectomy. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Survival Analysis. Treatment Outcome. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17649645.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


30. Somorácz A, Tátrai P, Horváth G, Kiss A, Kupcsulik P, Kovalszky I, Schaff Z: Agrin immunohistochemistry facilitates the determination of primary versus metastatic origin of liver carcinomas. Hum Pathol; 2010 Sep;41(9):1310-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Agrin immunohistochemistry facilitates the determination of primary versus metastatic origin of liver carcinomas.
  • In our earlier work, we demonstrated that agrin, a multifunctional heparan sulfate proteoglycan, accumulates in hepatocellular carcinoma (HCC) and cholangiocellular carcinoma (CCC).
  • Here, we have examined the expression of agrin in metastatic liver carcinomas in comparison with primary liver tumors.
  • Immunohistochemistry for agrin was performed on 25 HCC, 16 intrahepatic CCC, 20 colorectal cancer metastasis (CRCm), and 18 pancreatic ductal carcinoma metastasis (PDCm) samples and evaluated with both quantitative and qualitative methods.
  • Agrin mRNA expression was measured in 11 HCC, 7 CCC, 11 CRCm, and 12 normal liver tissues.
  • As opposed to HCC, agrin immunostaining was faint or nearly absent from the CD34-positive microvessels of CCC, CRCm, and PDCm; rather, it was detected in the basement membranes surrounding tumor cell pseudoglandules.
  • Thus, agrin immunohistochemistry may facilitate determination of primary versus metastatic origin in problematic liver cancer cases.
  • [MeSH-major] Adenoma, Liver Cell / pathology. Agrin / metabolism. Carcinoma, Hepatocellular / pathology. Colorectal Neoplasms / secondary. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Antigens, CD34 / metabolism. Bile Duct Neoplasms / genetics. Bile Duct Neoplasms / metabolism. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / metabolism. Bile Ducts, Intrahepatic / pathology. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Pancreatic Ductal / metabolism. Carcinoma, Pancreatic Ductal / secondary. Cholangiocarcinoma / genetics. Cholangiocarcinoma / metabolism. Cholangiocarcinoma / pathology. DNA, Neoplasm / analysis. Diagnosis, Differential. Endothelium, Vascular / metabolism. Endothelium, Vascular / pathology. Female. Gene Expression Regulation, Neoplastic. Hepatectomy. Humans. Male. Microvessels / metabolism. Microvessels / pathology. Middle Aged. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. RNA, Messenger / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20471664.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Agrin; 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / RNA, Messenger
  •  go-up   go-down


31. Savelov NA, Petrovichev NN, Anurova OA, Pavlovskaia AI, Tatosian AG: [Immunohistochemical diagnosis of metastases of small round cell carcinomas with undetected primary focus]. Arkh Patol; 2006 Mar-Apr;68(2):16-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunohistochemical diagnosis of metastases of small round cell carcinomas with undetected primary focus].
  • 17 small round cell tumors of unkown primary site were studied.
  • One of the following diagnosis was obtained in 14 cases (82.4%): small cell carcinoma, Merkel cell carcinoma, melanoma, Ewing sarcoma family tumor.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Small Cell / secondary. Liver Neoplasms / secondary. Neoplasms, Unknown Primary / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor. Carcinoma, Merkel Cell / diagnosis. Carcinoma, Merkel Cell / secondary. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Lymphoma / pathology. Male. Middle Aged. Sarcoma, Ewing / diagnosis. Sarcoma, Ewing / secondary

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16752503.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


32. Ceafalan L, Vidulescu C, Radu E, Regalia T, Popescu I, Pana M, Serghei L, Voiculescu B, Popescu LM: [Expression of stem cell markers on fetal and tumoral human liver cells in primary culture]. Rev Med Chir Soc Med Nat Iasi; 2005 Jan-Mar;109(1):96-104
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of stem cell markers on fetal and tumoral human liver cells in primary culture].
  • We have identified populations expressing these markers in both fetal and tumoral human liver by flow cytometry, using monoclonal antibodies against CD90, CD117, CD34, and HLA-DR.
  • In tumoral liver CD117+/CD90+ cells were found in decreasing number from the neoplastic (2.48 +/- 0.67) and peritumoral region (0.88 +/- 0.12) to the area of para-tumoral (normal) parenchyma (0.13 +/- 0.04).
  • Using the same markers on fetal liver cells we have also identified small populations of CD117+/CD90+ cells (0.28 +/- 0.07%) and CD117+/CD34+ cells (1.13 +/- 0.24%), presumably resident stem cells or hematopoietic stem cells.
  • Immunomagnetic negative separation was then performed on fetal liver cells using monoclonal antibodies against specific markers of hematopoietic lineages such as CD3, 14, 16, 19, 22, and CD56 to eliminate this population.
  • Isolation using appropriate markers and initiation of primary cultures is a first step to the therapeutic use of fetal stem cells and for the study of adult liver stem cells involvement in carcinogenesis.
  • [MeSH-major] Biomarkers / analysis. Biomarkers, Tumor / analysis. Carcinoma, Hepatocellular / immunology. Fetus. Hepatocytes / immunology. Liver Neoplasms / immunology. Stem Cells
  • [MeSH-minor] Adult. Antigens, CD34 / analysis. Antigens, Thy-1 / analysis. Flow Cytometry. HLA-DR Antigens / analysis. Humans. Immunomagnetic Separation. Microscopy, Fluorescence. Proto-Oncogene Proteins c-kit / analysis. Stem Cell Transplantation / methods

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607835.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antigens, Thy-1; 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / HLA-DR Antigens; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


33. Abe K, Thung SN, Wu HC, Tran TT, Le Hoang P, Truong KD, Inui A, Jang JJ, Su IJ: Pre-S2 deletion mutants of hepatitis B virus could have an important role in hepatocarcinogenesis in Asian children. Cancer Sci; 2009 Dec;100(12):2249-54
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although many studies on the risk factors and their carcinogenesis in adult hepatocellular carcinoma (HCC) have been reported, they remain poorly understood in childhood HCC.
  • The HBV pre-S2 deletion mutant at nt 4-57 which has a CD8 T-cell epitope could be responsible for the emergence and aggressive outcome of childhood HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Gene Deletion. Hepatitis B Surface Antigens / genetics. Hepatitis B virus / genetics. Liver Neoplasms / etiology. Protein Precursors / genetics

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19719772.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hepatitis B Surface Antigens; 0 / Protein Precursors; 0 / presurface protein 2, hepatitis B surface antigen
  •  go-up   go-down


34. Yuan ZY, Guan ZZ, Zhou ZM, Xia Y, Huang WZ, Yang XL: [Extrapulmonary small cell carcinoma in 52 patients]. Ai Zheng; 2006 Sep;25(9):1131-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extrapulmonary small cell carcinoma in 52 patients].
  • BACKGROUND & OBJECTIVE: The majority of small cell carcinoma occurs in the lung.
  • Extrapulmonary small cell carcinoma (ESCC) has been recognized as a clinicopathologic entity distinct from small cell carcinoma of the lung.
  • Of the 53 cases of ESCC, 33 (62.3%) were detected in the esophagus, 5 in the cervix, 4 in the larynx, 3 in the pharynx, 2 in the upper sinus, 2 in the rectum and sublingual gland, 1 in the thyroid gland, 1 in the pleura, and 1 in the liver.
  • CONCLUSIONS: ESCC is identified in various sites, with the most common primary site being the esophagus.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell. Esophageal Neoplasms. Radiotherapy, High-Energy
  • [MeSH-minor] Adult. Aged. Cobalt Radioisotopes. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / surgery. Male. Middle Aged. Particle Accelerators. Retrospective Studies. Survival Rate. Treatment Outcome. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965656.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cobalt Radioisotopes
  •  go-up   go-down


35. Huang JH, Wu PH, Gu YK, Zhang FJ, Li CX, Gao F, Zhang L, Fan WJ, Li CJ: [Study on primary hepatocellular carcinoma associated with hypersplenism treated by partial splenic embolization combined with hepatic arterial chemoembolization]. Ai Zheng; 2006 Aug;25(8):1003-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study on primary hepatocellular carcinoma associated with hypersplenism treated by partial splenic embolization combined with hepatic arterial chemoembolization].
  • BACKGROUND & OBJECTIVE: 70-90% of patients of primary hepatocellular carcinoma (PHC) are associated with liver cirrhosis, portal hypertension and hypersplenism.
  • The treatment of PHC is usually hampered by low or slow recovery of blood cell counts.
  • RESULTS: Satisfactory effects were achieved in PSE combined with TACE group in terms of correction of blood cell counts compared with cases treated with TACE alone.
  • CONCLUSION: PSE associated with TACE is safe and effective for the treatment of patients with PHC associated with liver cirrhosis, portal hypertension and hypersplenism.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic. Hypersplenism / therapy. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Blood Cell Count. Embolization, Therapeutic / methods. Female. Hepatic Artery. Humans. Iodized Oil. Male. Splenic Artery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965683.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 8001-40-9 / Iodized Oil
  •  go-up   go-down


36. Kinoshita Y, Tajiri T, Souzaki R, Tatsuta K, Higashi M, Izaki T, Takahashi Y, Taguchi T: Diagnostic value of lectin reactive alpha-fetoprotein for neoinfantile hepatic tumors and malignant germ cell tumors: preliminary study. J Pediatr Hematol Oncol; 2008 Jun;30(6):447-50
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of lectin reactive alpha-fetoprotein for neoinfantile hepatic tumors and malignant germ cell tumors: preliminary study.
  • BACKGROUND AND PURPOSE: The serum alpha-fetoprotein (AFP) level has been used as a tumor marker for hepatoblastoma, and malignant germ cell tumors in pediatric patients.
  • The AFP has 3 isoforms (L1, L2, L3), and the usefulness of the L3 fraction as a diagnostic marker for the adult hepatocellular carcinoma is well known.
  • MATERIALS AND METHODS: From 2003 to 2006, two cases of hepatoblastoma, and 5 cases of germ cell tumor, all of which were neoinfantile, were treated in our department.
  • DISCUSSION: Our results indicated that the level of the L3 fraction accurately confirmed the existence, or the malignant potential of hepatic tumor or germ cell tumor.
  • [MeSH-major] Biomarkers, Tumor / blood. Hepatoblastoma / blood. Liver Neoplasms / blood. Neoplasms, Germ Cell and Embryonal / blood. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18525461.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lectins; 0 / Protein Isoforms; 0 / alpha-Fetoproteins
  •  go-up   go-down


37. Gao WB, Han JD, Du M: [Observation on efficiency of shelian capsule as adjuvant of embolismic chemotherapy on primary hepatic carcinoma]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2005 Nov;25(11):980-2
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Observation on efficiency of shelian capsule as adjuvant of embolismic chemotherapy on primary hepatic carcinoma].
  • OBJECTIVE: To evaluate the clinical efficacy and side effects of Shelian capsule (SLC) as adjuvant of embolismic chemotherapy on primary hepatic carcinoma.
  • METHODS: One hundred and twenty patients with hepatic carcinoma were conducted arterial embolismic chemotherapy with FAM program for two therapeutic cycles.
  • The tumor size, Karnofsky score, clinical symptoms, alpha fetoprotein (AFP), NK cell, T cell-subgroup and adverse effect before and after treatment between the two groups were compared respectively.
  • The ratio of CD4/CD8 and NK cell activity was significantly different between the two groups (P<0.05).

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16355611.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Capsules; 0 / Drugs, Chinese Herbal; 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; U3P01618RT / Fluorouracil
  •  go-up   go-down


38. Liang YM, Li XH, Lü YL, Zhong M: [Morphology and immunohistochemical characteristics of hepatic primary and metastatic malignant spindle cell tumors]. Zhonghua Yi Xue Za Zhi; 2005 Jan 12;85(2):96-100
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Morphology and immunohistochemical characteristics of hepatic primary and metastatic malignant spindle cell tumors].
  • OBJECTIVE: To investigate the morphology and immunohistochemical characteristics of hepatic primary and metastatic malignant spindle cell tumors, and to conclude the diagnostic and differential diagnostic criteria for these morphologically similar tumors.
  • METHODS: Forty-six specimens of hepatic spindle cell tumors.
  • 20 primary tumors (43.4%), including 3 cases of sarcomatoid carcinoma (6.5%), 11 of angiosarcoma (23.9%), 2 of epithelioid hemangioendothelioma (5%), 1 of spindle cell carcinoid (2.2%), and 3 of undifferentiated sarcoma (6.5%).
  • and 26 metastatic malignant tumors (56.5%), including 20 cases of gastrointestinal stromal tumors (GIST, 43.4%), 3 of leiomyosarcoma (6.5%), 2 of malignant peripheral never sheath tumor (4.3%), and 1 of meningeal hemangiopericytoma (2.2%), resected during operation or collected during imaging-mediated liver puncture underwent hematoxylin-eosin staining, SP staining, and EnVision immunohistochemical staining.
  • RESULTS: Either primary or metastatic tumors showed extensive overlapping in histopathologic appearance, and hemangiopericytoma-like structure was the predominant pattern, which could be seen in nearly every kind of hepatic spindle cell tumors.
  • Most stromal tumor cases were CD117 positive, and existed the condition that the primary tumor was positive and the metastatic tumor was negative or vice versa or one part of specimen was positive but other part was negative.
  • Sarcomatoid carcinoma was positive for CK and vimentin.
  • Spindle cell carcinoid was positive for CK and neuroendocrine markers, such as synaptophysin and chromogranin A.
  • CONCLUSION: Primary angiosarcoma is the most common form of primary spindle cell tumor in liver, and metastatic GIST is predominant in hepatic metastatic spindle cell tumors.
  • [MeSH-major] Carcinoma / pathology. Hemangiosarcoma / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD31 / biosynthesis. Antigens, CD34 / biosynthesis. Biomarkers, Tumor. Child. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15774214.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Antigens, CD34; 0 / Biomarkers, Tumor
  •  go-up   go-down


39. Pawlik TM, Gleisner AL, Bauer TW, Adams RB, Reddy SK, Clary BM, Martin RC, Scoggins CR, Tanabe KK, Michaelson JS, Kooby DA, Staley CA, Schulick RD, Vauthey JN, Abdalla EK, Curley SA, Choti MA, Elias D: Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multi-center analysis. Ann Surg Oncol; 2007 Oct;14(10):2807-16
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multi-center analysis.
  • BACKGROUND: The role of hepatic resection for metastatic squamous cell carcinoma (SCC) remains unknown.
  • The current study evaluates the role of hepatic resection in patients with metastatic SCC to the liver.
  • RESULTS: Primary SCC site was anal (n = 27), head/neck (n = 12), lung (n = 4), esophagus (n = 2), and other (n = 7).
  • Treatment of primary SCC was chemotherapy +/- radiotherapy alone (n = 29), chemotherapy +/- radiotherapy + surgery (n = 15), or surgery alone (n = 8).
  • Factors associated with reduced DFS were liver tumor size > 5 cm (hazard ratio (HR) = 2.02) and positive surgical margin (HR = 2.33).
  • Long-term survival, however, can be achieved following surgical resection of SCC liver metastasis, especially in patients who present with limited metachronous disease amenable to margin negative resection.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / secondary. Electrocoagulation. Esophageal Neoplasms / surgery. Head and Neck Neoplasms / surgery. Hepatectomy. Liver Neoplasms / secondary. Lung Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Prognosis. Retreatment. United States


40. Ward SC, Huang J, Tickoo SK, Thung SN, Ladanyi M, Klimstra DS: Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation. Mod Pathol; 2010 Sep;23(9):1180-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation.
  • Fibrolamellar carcinoma is a rare malignant primary liver neoplasm with characteristic histological features that typically arises in young patients without viral hepatitis or cirrhosis.
  • In contrast to classical hepatocellular carcinoma, individual cases of fibrolamellar carcinoma have been reported to express cytokeratin 7.
  • In addition, ultrastructural and serological studies have suggested that fibrolamellar carcinoma may show neuroendocrine differentiation.
  • The cellular differentiation of fibrolamellar carcinoma has not been studied and little is reported about its immunohistochemical profile.
  • We studied 26 cases of fibrolamellar carcinoma and 62 cases of classical hepatocellular carcinoma by immunohistochemistry for HepPar1, glypican-3, pCEA, CD10, alpha-fetoprotein, cytokeratin 20, neuroendocrine markers, and surrogate markers for biliary differentiation (cytokeratin 7, cytokeratin 19, epithelial membrane antigen, EpCAM, mCEA, B72.3, and CA19.9).
  • Tumor cells of fibrolamellar carcinoma and hepatocellular carcinoma showed positive signals for albumin mRNA by in situ hybridization in all cases.
  • Both tumor types stained uniformly positively with HepPar1 and most showed a canalicular staining pattern for pCEA, confirming their hepatocellular differentiation.
  • In addition, 39% of hepatocellular carcinoma cases and 59% of fibrolamellar carcinoma cases were positive for glypican-3.
  • All 22 fibrolamellar carcinoma cases tested showed positive staining for cytokeratin 7 and epithelial membrane antigen, whereas less than one-third of hepatocellular carcinoma cases were positive for these markers (P<0.0001).
  • Further, 36% of fibrolamellar carcinoma cases showed staining for B72.3, cytokeratin 19, EpCAM, or mCEA.
  • Therefore, cytokeratin 7 and epithelial membrane antigen may be useful to differentiate between fibrolamellar carcinoma and hepatocellular carcinoma.
  • On the basis of immunohistochemistry, fibrolamellar carcinoma seems to show both hepatocellular and bile duct differentiation.
  • [MeSH-major] Bile Ducts / pathology. Hepatocytes / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Cell Differentiation. Female. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. Tissue Array Analysis

  • Genetic Alliance. consumer health - Fibrolamellar carcinoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20495535.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; Fibrolamellar hepatocellular carcinoma
  •  go-up   go-down


41. West J, Wood H, Logan RF, Quinn M, Aithal GP: Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001. Br J Cancer; 2006 Jun 5;94(11):1751-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001.
  • In the last two decades, mortality from primary liver cancer has increased in the UK.
  • We calculated directly age-standardised incidence rates (using the European standard population) by subsite and histological type for all cancers of the liver, gallbladder and biliary tract in England and Wales from 1971 to 2001, using cancer registry data.
  • The incidence of cancers of the liver, gallbladder and biliary tract increased, with the greatest rise, around 12-fold, in intrahepatic bile duct cancers.
  • The rate of liver cell cancer increased by around 45% in males, but by <10% in females.
  • Cholangiocarcinoma increased around 16-fold and became the most common type of primary liver cancer in females, while hepatocellular carcinoma remained the commonest type in males.
  • The age-specific incidence rates showed that intrahepatic bile duct cancer continued to increase throughout the 1990s in those aged 75 and over, while liver cell cancer decreased in the older age groups.
  • In conclusion, there were increases in the incidence of primary liver cancer, which have been particularly dramatic for intrahepatic bile duct cancer, over the last three decades of the 20th century in England and Wales.
  • [MeSH-major] Biliary Tract Neoplasms / epidemiology. Liver Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. England / epidemiology. Female. Humans. Incidence. Male. Middle Aged. Registries. Sex Characteristics. Wales / epidemiology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2005 Apr;54(4):533-9 [15753540.001]
  • [Cites] Health Stat Q. 2004 Autumn;(23):7-17 [15704380.001]
  • [Cites] Gut. 2001 Jun;48(6):816-20 [11358902.001]
  • [Cites] Hepatology. 2001 Jun;33(6):1353-7 [11391522.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):745-50 [10072408.001]
  • [Cites] Gastroenterology. 2005 Mar;128(3):620-6 [15765398.001]
  • [Cites] Gut. 1989 May;30(5):695-700 [2731765.001]
  • [Cites] Popul Trends. 1996 Winter;(86):29-35 [8987096.001]
  • [Cites] Lancet. 1997 Oct 18;350(9085):1142-3 [9343506.001]
  • [Cites] J Hepatol. 2004 Mar;40(3):472-7 [15123362.001]
  • [Cites] Gastrointest Endosc. 1988 May-Jun;34(3):277-8 [3292346.001]
  • (PMID = 16736026.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2361300
  •  go-up   go-down


42. Liu ZZ, Huang WY, Lin JS, Li XS, Liang KH, Huang JL: Cell cycle and radiosensitivity of progeny of irradiated primary cultured human hepatocarcinoma cells. World J Gastroenterol; 2005 Nov 28;11(44):7033-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell cycle and radiosensitivity of progeny of irradiated primary cultured human hepatocarcinoma cells.
  • AIM: To evaluate the change of growth characteristics and radiosensitivity of irradiated primary cultured human hepatocarcinoma cells.
  • We divided the samples into irradiated group and non-irradiated group and measured their plating efficiency (PE), population doubling time (PDT), radiosensitivity index SF2 and cell cycle.
  • RESULTS: The PDT of primary culture of hepatocarcinoma cells was 91.0+/-6.6 h, PE was 12.0+/-1.4%, SF2 was 0.41+/-0.05%.
  • The primary cultured human hepatocarcinoma cells showed significant S reduction and G(2) arrest in a dose-dependent manner.
  • The progeny of irradiated primary cultured hepatocarcinoma cells grew more slowly and its radiosensitivity increased.
  • CONCLUSION: The progeny of irradiated primary cultured human hepatocarcinoma cells grows more slowly and its radiosensitivity increases.
  • [MeSH-major] Carcinoma, Hepatocellular. Cell Cycle / physiology. Liver Neoplasms. Radiation Tolerance. Tumor Cells, Cultured / physiology. Tumor Cells, Cultured / radiation effects
  • [MeSH-minor] Adult. Aged. Cell Survival. Humans. Middle Aged. X-Rays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437612.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4717050
  •  go-up   go-down


43. Verslype C, Libbrecht L: The multidisciplinary management of gastrointestinal cancer. The diagnostic and therapeutic approach for primary solid liver tumours in adults. Best Pract Res Clin Gastroenterol; 2007;21(6):983-96
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The multidisciplinary management of gastrointestinal cancer. The diagnostic and therapeutic approach for primary solid liver tumours in adults.
  • The finding of a focal solid liver lesion represents a challenge for the clinician in terms of the most optimal diagnostic and therapeutic algorithm.
  • Tumours may arise from hepatocytes (hepatocellular adenoma, dysplastic nodules and carcinoma), bile ducts (cholangiocarcinoma) or mesenchymal tissue (hemangioma, epithelioid haemangioendothelioma), or are metastases from primary tumours outside the liver.
  • However, small hypervascular lesions in a cirrhotic liver may be difficult to characterise.
  • More insight has been gathered recently in the histological classification of hepatocellular adenomas, but the differential diagnosis by imaging of adenoma versus FNH or well-differentiated hepatocellular carcinoma remains often difficult.
  • The therapy of a focal liver lesion is determined by its natural history and the functional status of the surrounding liver parenchyma.
  • Selected patients with primary liver cancer are candidates for liver transplantation, while patients with advanced malignant tumours have a poor outcome.
  • [MeSH-major] Bile Duct Neoplasms. Liver Cirrhosis / complications. Liver Neoplasms. Precancerous Conditions
  • [MeSH-minor] Adenoma, Liver Cell / diagnosis. Adenoma, Liver Cell / etiology. Adenoma, Liver Cell / therapy. Adult. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / etiology. Carcinoma, Hepatocellular / therapy. Cholangiocarcinoma / diagnosis. Cholangiocarcinoma / etiology. Cholangiocarcinoma / therapy. Diagnosis, Differential. Focal Nodular Hyperplasia / diagnosis. Focal Nodular Hyperplasia / etiology. Focal Nodular Hyperplasia / therapy. Hemangioma / diagnosis. Hemangioma / etiology. Hemangioma / therapy. Humans

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18070699.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 47
  •  go-up   go-down


44. Karamitopoulou E, Cioccari L, Jakob S, Vallan C, Schaffner T, Zimmermann A, Brunner T: Active caspase 3 and DNA fragmentation as markers for apoptotic cell death in primary and metastatic liver tumours. Pathology; 2007 Dec;39(6):558-64
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Active caspase 3 and DNA fragmentation as markers for apoptotic cell death in primary and metastatic liver tumours.
  • AIMS: The induction of tumour cell death by apoptosis is a major goal of cancer therapy and the in situ detection of apoptosis in tumour tissue has become an important diagnostic parameter.
  • Different apoptosis detection methods assess distinct biochemical processes in the dying cell.
  • The aim of this study was to compare the immunohistochemical detection of active caspase 3 and single-stranded DNA in primary and metastatic liver tumours as markers of apoptotic cell death.
  • METHODS: We studied detection of active caspase 3 and single-stranded DNA in 20 primary hepatocellular carcinomas (HCC) and 20 liver metastases from colorectal carcinomas (CRC) using immunohistochemistry on paraffin sections.
  • CONCLUSION: The sensitivity of apoptosis detection using immunohistochemistry for active caspase 3 and single-stranded DNA may be tumour cell type dependent.
  • [MeSH-major] Apoptosis. Carcinoma, Hepatocellular / enzymology. Carcinoma, Hepatocellular / genetics. Caspase 3 / metabolism. Colorectal Neoplasms / enzymology. DNA Fragmentation. Liver Neoplasms / enzymology. Liver Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Cell Line, Tumor. DNA, Neoplasm. DNA, Single-Stranded. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18027258.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / DNA, Single-Stranded; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


45. Kwon JB, Park K, Kim YD, Seo JH, Moon SW, Cho DG, Kim YW, Kim DG, Yoon SK, Lim HW: Clinical outcome after pulmonary metastasectomy from primary hepatocellular carcinoma: analysis of prognostic factors. World J Gastroenterol; 2008 Oct 7;14(37):5717-22
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome after pulmonary metastasectomy from primary hepatocellular carcinoma: analysis of prognostic factors.
  • At the end of the follow-up, 1 patient died from hepatic failure without recurrence, 6 died from hepatic failure with a recurrent hepatocellular carcinoma (HCC), and 4 died from recurrent HCC with cachexia.
  • Among several clinical factors, Kaplan-Meier analysis revealed that liver transplantation as a treatment for the primary lesion, grade of cell differentiation, and negative evidence HBV infection were independent predictive factors.
  • Although not significant, patients with liver transplantation of a primary HCC survived longer.
  • Liver transplantation might be the most beneficial modality that can offer patients better survival.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / therapy. Lung Neoplasms / surgery. Pulmonary Surgical Procedures
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Cell Differentiation. Female. Hepatectomy. Hepatitis B / complications. Humans. Kaplan-Meier Estimate. Liver Transplantation / adverse effects. Male. Middle Aged. Patient Selection. Proportional Hazards Models. Risk Assessment. Risk Factors. Thoracoscopy. Thoracotomy. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 1997 Jan-Feb;44(13):251-7 [9058154.001]
  • [Cites] Gastroenterology. 1996 Sep;111(3):720-6 [8780578.001]
  • [Cites] Br J Surg. 1998 Sep;85(9):1198-200 [9752858.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Nov;54(5):415-20 [15235823.001]
  • [Cites] J Chin Med Assoc. 2004 Dec;67(12):621-4 [15779485.001]
  • [Cites] World J Surg. 2005 Jun;29(6):715-8 [16078127.001]
  • [Cites] J Hepatol. 2005 Oct;43(4):584-9 [16120468.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Nov;20(11):1781-7 [16246200.001]
  • [Cites] Am J Surg. 2006 Jul;192(1):46-51 [16769274.001]
  • [Cites] Hepatogastroenterology. 2007 Jan-Feb;54(73):152-6 [17419251.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Jul 1;26(1):87-94 [17555425.001]
  • [Cites] J Thorac Cardiovasc Surg. 1965 Mar;49:357-63 [14265951.001]
  • [Cites] Ann Thorac Surg. 1999 Nov;68(5):1815-20 [10585064.001]
  • [Cites] Radiology. 2000 Sep;216(3):698-703 [10966697.001]
  • [Cites] Hepatogastroenterology. 2001 Jul-Aug;48(40):1088-93 [11490807.001]
  • [Cites] J Am Coll Surg. 2002 Sep;195(3):311-8 [12229937.001]
  • [Cites] World J Gastroenterol. 2004 Jun 1;10(11):1688-9 [15162554.001]
  • [Cites] Hepatogastroenterology. 2004 May-Jun;51(57):825-9 [15143926.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2002;9(3):386-8 [12353153.001]
  • [Cites] Hepatogastroenterology. 2004 Sep-Oct;51(59):1428-33 [15362769.001]
  • [Cites] Radiol Clin North Am. 2004 Nov;42(6):1123-39, ix [15488562.001]
  • [Cites] Cancer. 1984 Feb 1;53(3):401-5 [6198058.001]
  • [Cites] Semin Surg Oncol. 1990;6(5):297-302 [2237090.001]
  • [Cites] Hepatogastroenterology. 1993 Aug;40(4):316-9 [7691699.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(1):86-92 [9683759.001]
  • (PMID = 18837090.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2748208
  •  go-up   go-down


46. Ma H, Zhang Y, Wang Q, Li Y, He J, Wang H, Sun J, Pan K, Chen M, Xia J: Therapeutic safety and effects of adjuvant autologous RetroNectin activated killer cell immunotherapy for patients with primary hepatocellular carcinoma after radiofrequency ablation. Cancer Biol Ther; 2010 Jun 1;9(11):903-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic safety and effects of adjuvant autologous RetroNectin activated killer cell immunotherapy for patients with primary hepatocellular carcinoma after radiofrequency ablation.
  • Hepatocellular carcinoma (HCC) recurs frequently after minimally invasive therapy.
  • These preliminary results suggest the feasability and safety of the combined therapeutic regimen for HCC, and that the RAK cell adoptive immunotherapy might be helpful in preventing recurrence in HCC patients after RFA.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Catheter Ablation. Immunotherapy, Adoptive / methods. Killer Cells, Natural / transplantation. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Antigens, CD / metabolism. Cell Line, Tumor. Cells, Cultured. Combined Modality Therapy. Cytotoxicity Tests, Immunologic. Cytotoxicity, Immunologic / immunology. Female. Fibronectins / immunology. Hep G2 Cells. Humans. Immunophenotyping. Interferon-gamma / metabolism. Lymphocyte Activation / immunology. Lymphocytes / immunology. Lymphocytes / metabolism. Male. Middle Aged. Recombinant Proteins / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20364106.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Fibronectins; 0 / Recombinant Proteins; 0 / retronectin; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


47. Agarwal R, Levinson AW, Schowinsky J, Su LM: Large mixed epithelial and stromal tumor of the kidney masquerading as metastatic renal cell carcinoma. Urology; 2007 Nov;70(5):1008.e17-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large mixed epithelial and stromal tumor of the kidney masquerading as metastatic renal cell carcinoma.
  • We report the case of a 39-year-old woman with a large right renal mass 20 cm in size with heterogeneous solid and cystic components as well as concurrent liver lesions suspicious for metastatic renal cell carcinoma.
  • Surgical extirpation of the renal mass and liver lesions was performed laparoscopically with the pathological analysis revealing a rare renal neoplasm--mixed epithelial and stromal tumor of the kidney--and adenomas of the liver.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Liver Neoplasms / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18068474.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Staehler MD, Kruse J, Haseke N, Stadler T, Roosen A, Karl A, Stief CG, Jauch KW, Bruns CJ: Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis. World J Urol; 2010 Aug;28(4):543-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis.
  • The value of surgical resection of renal cell carcinoma (RCC) liver metastases still remains unclear.
  • OBJECTIVE: Of our study was to evaluate the efficacy of liver resection by comparing patients who could have undergone metastasectomy due to limited disease, but refused surgery.
  • MATERIALS AND METHODS: Eighty-eight patients were identified with liver metastases and indication of surgery between 1995 and 2006.
  • In 68 patients, liver resection was performed, 20 patients denied surgery and served as comparison group.
  • Median amount of liver metastases was 2 (range 1-30).
  • Low-grade primary RCC had a MS of 155 (95% CI 123-187) months compared to 29 (95% CI 8-50) months without resection (P = 0.0036).
  • CONCLUSIONS: Liver metastasectomy is an independent valuable tool in the treatment of metastatic RCC and significantly prolongs patient's survival, even if further systemic treatment is necessary.
  • With the evidence given, patients may benefit from liver metastasis resection if technically feasible.
  • [MeSH-major] Carcinoma, Renal Cell. Kidney Neoplasms / mortality. Kidney Neoplasms / pathology. Liver / surgery. Liver Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Databases, Factual. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Proportional Hazards Models. Retrospective Studies. Young Adult


49. Taweemonkongsap T, Nualyong C, Leewansangtong S, Amornvesukit T, Sirivatanauksorn Y, Tantiwong A, Soontrapa S: Surgical treatment of renal cell carcinoma with inferior vena cava thrombus: using liver mobilization technique to avoid cardiopulmonary bypass. Asian J Surg; 2008 Apr;31(2):75-82
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of renal cell carcinoma with inferior vena cava thrombus: using liver mobilization technique to avoid cardiopulmonary bypass.
  • OBJECTIVE: To evaluate the results of surgical treatment of renal cell carcinoma (RCC) with inferior vena cava (IVC) thrombus and describe the use of a transabdominal approach with liver mobilization to avoid cardiopulmonary bypass (CPB).
  • One patient had colonic injury requiring primary repair.

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18490219.001).
  • [ISSN] 1015-9584
  • [Journal-full-title] Asian journal of surgery
  • [ISO-abbreviation] Asian J Surg
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 30
  •  go-up   go-down


50. Turato C, Ruvoletto MG, Biasiolo A, Quarta S, Tono N, Bernardinello E, Beneduce L, Fassina G, Cavalletto L, Chemello L, Merkel C, Gatta A, Pontisso P: Squamous cell carcinoma antigen-1 (SERPINB3) polymorphism in chronic liver disease. Dig Liver Dis; 2009 Mar;41(3):212-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma antigen-1 (SERPINB3) polymorphism in chronic liver disease.
  • BACKGROUND: The serpin squamous cell carcinoma antigen (SCCA, SERPINB3) has been found over-expressed in primary liver cancer and at lower extent in cirrhosis and chronic hepatitis.
  • AIM: To explore SCCA-1 polymorphism in patients with HCV infection as single etiologic factor and different extent of liver disease.
  • CONCLUSIONS: The newly identified SCCA-PD variant was more frequently found in liver cirrhosis, suggesting that patients carrying this polymorphism are more prone to develop progressive liver fibrosis.
  • [MeSH-major] Antigens, Neoplasm / genetics. Liver Diseases / genetics. Polymorphism, Restriction Fragment Length. Serpins / genetics
  • [MeSH-minor] Adult. Case-Control Studies. Chronic Disease. Female. Humans. Immunoglobulin M / blood. Male. Middle Aged

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18657489.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Immunoglobulin M; 0 / Serpins; 0 / squamous cell carcinoma-related antigen
  •  go-up   go-down


51. Liu LX, Lee NP, Chan VW, Xue W, Zender L, Zhang C, Mao M, Dai H, Wang XL, Xu MZ, Lee TK, Ng IO, Chen Y, Kung HF, Lowe SW, Poon RT, Wang JH, Luk JM: Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma. Hepatology; 2009 Nov;50(5):1453-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma.
  • Hepatocellular carcinoma (HCC) is a lethal malignancy for which there are no effective therapies.
  • Here, we show that cadherin-17 (CDH17) adhesion molecule is up-regulated in human liver cancers and can transform premalignant liver progenitor cells to produce liver carcinomas in mice.
  • RNA interference-mediated knockdown of CDH17 inhibited proliferation of both primary and highly metastatic HCC cell lines in vitro and in vivo.
  • The antitumor mechanisms underlying CDH17 inhibition involve inactivation of Wnt signaling, because growth inhibition and cell death were accompanied by relocalization of beta-catenin to the cytoplasm and a concomitant reduction in cyclin D1 and an increase in retinoblastoma.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Apoptosis. 2006 Jul;11(7):1215-29 [16699959.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2005;70:251-61 [16869761.001]
  • [Cites] Cell Mol Life Sci. 2006 Jul;63(13):1564-73 [16791429.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5248-52 [16951245.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):94-9 [17063305.001]
  • [Cites] J Mol Biol. 2007 Jul 6;370(2):220-30 [17512947.001]
  • [Cites] Hepatology. 2007 Jul;46(1):200-8 [17596871.001]
  • [Cites] Bioinformatics. 2007 Jul 1;23(13):i450-8 [17646330.001]
  • [Cites] Dis Colon Rectum. 2007 Nov;50(11):1873-80 [17828401.001]
  • [Cites] Curr Opin Oncol. 2008 Jan;20(1):90-6 [18043262.001]
  • [Cites] Br J Cancer. 2008 Jan 15;98(1):4-8 [18182973.001]
  • [Cites] J Mol Biol. 2008 Apr 18;378(1):44-54 [18342884.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2008 May;20(4):275-83 [18353622.001]
  • [Cites] Gastroenterology. 2008 May;134(6):1752-63 [18471552.001]
  • [Cites] Proteomics. 2008 May;8(10):2136-49 [18425728.001]
  • [Cites] Mutat Res. 2008 May 31;653(1-2):6-13 [18467159.001]
  • [Cites] Cell. 2008 Nov 28;135(5):852-64 [19012953.001]
  • [Cites] Cell. 2006 Jun 30;125(7):1253-67 [16814713.001]
  • [Cites] Cell. 2009 Mar 20;136(6):1136-47 [19303855.001]
  • [Cites] Hepatology. 2000 Jan;31(1):173-81 [10613743.001]
  • [Cites] Gut. 2001 Jul;49(1):73-81 [11413113.001]
  • [Cites] World J Gastroenterol. 2001 Oct;7(5):630-6 [11819844.001]
  • [Cites] Cancer Sci. 2003 May;94(5):425-30 [12824888.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):334-41 [12845670.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Nov 21;311(3):618-24 [14623315.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jan 1;148(1):80-4 [14697646.001]
  • [Cites] Liver Transpl. 2004 Feb;10(2 Suppl 1):S39-45 [14762838.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jun 25;319(2):562-8 [15178443.001]
  • [Cites] Cancer Lett. 2004 Aug 30;212(2):253-9 [15279905.001]
  • [Cites] J Clin Microbiol. 1987 Nov;25(11):2140-4 [2447120.001]
  • [Cites] Science. 1994 Apr 15;264(5157):430-3 [8153632.001]
  • [Cites] J Cell Biol. 1994 Jun;125(6):1353-69 [8207063.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):483-9 [15701831.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Virchows Arch. 2005 Oct;447(4):717-22 [16044349.001]
  • [Cites] J Clin Invest. 2006 Jun;116(6):1582-95 [16710476.001]
  • [ErratumIn] Hepatology. 2010 Jan;51(1):358
  • (PMID = 19676131.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] ENG
  • [Grant] United States / Howard Hughes Medical Institute / / ; United States / NCI NIH HHS / CA / P01 CA013106; United States / NCI NIH HHS / CA / P30 CA008748; United States / NCI NIH HHS / CA / CA13106
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDH17 protein, human; 0 / Cadherins; 0 / Cdh17 protein, mouse; 0 / Wnt Proteins; 0 / beta Catenin
  • [Other-IDs] NLM/ HHMIMS353854; NLM/ PMC3328302
  •  go-up   go-down


52. Zhang YX, Wang XY, Liu JB, Zhang SQ, Chen YR: [Effects of auto-tumor infiltrating lymphocytes induced by interleukin (IL)-12 with IL-2 on patients of primary hepatic carcinoma]. Zhonghua Yi Xue Za Zhi; 2008 Apr 8;88(14):973-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of auto-tumor infiltrating lymphocytes induced by interleukin (IL)-12 with IL-2 on patients of primary hepatic carcinoma].
  • OBJECTIVE: To investigate the effects of the tumor infiltrating lymphocytes (TILs) from primary hepatic carcinoma (PHC) induced by interleukin-12 (IL-12) with IL-2, on their cytotoxicity, proliferation, and cytokine production, and the immunological function and survival of the PHC patients.
  • The cytotoxicity of the TILs of the IL-12 + IL-2 group against the autologous hepatic carcinoma cells was greater than that of the TILs of the IL-2 group (P < 0.05).
  • CONCLUSION: TILs from primary hepatic carcinoma induced by IL-12 can obviously enhance specific cytotoxicity and proliferation of TILs.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Interleukin-12 / pharmacology. Interleukin-2 / pharmacology. Liver Neoplasms / pathology. Lymphocytes, Tumor-Infiltrating / drug effects
  • [MeSH-minor] Adult. Aged. Cell Proliferation / drug effects. Cytotoxicity, Immunologic / drug effects. Follow-Up Studies. Humans. Immunotherapy, Adoptive. Middle Aged. Postoperative Care. Postoperative Period. Survival Analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18756970.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Interleukin-2; 187348-17-0 / Interleukin-12
  •  go-up   go-down


53. Zhao GP, Zhou ZG, Lei WZ, Wang C, Zheng XL, Zheng YC: [Expression of phosphatase of regeneration liver-3 in human colorectal carcinoma and its prognosis value]. Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Sep;11(5):487-91
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of phosphatase of regeneration liver-3 in human colorectal carcinoma and its prognosis value].
  • OBJECTIVE: To investigate the expression of phosphatase of regeneration liver-3(PRL-3) protein and its relationship with tumor invasion and metastasis in human colorectal carcinoma,and elucidate prognostic value.
  • METHODS: Immunohistochemistry method was applied to detect the PRL-3 expression in the primary tumor specimens and paired paratumor normal tissues from 46 colorectal carcinoma patients, the adenoma tissues from 6 patients with colorectal adenoma, all the metastatic lymph nodes from 29 cases and the metastatic liver lesions from 6 cases.
  • In colorectal carcinoma tissues, PRL-3 expression was confirmed in 26 of 46 cases (56.5%) of primary colorectal carcinomas (with lymph node metastasis 63.0%, without lymph node metastasis 37.0%, P=0.001), 26 of 29 (89.7%) lymph node metastases, and 5 of 6 liver metastases.
  • The expression of PRL-3 was assembled in the cytoplasm of carcinoma cells and more intensively on the cell membrane.Analysis of the relationship between PRL-3 expression and the clinicopathologic features showed that PRL-3 expression was closely associated with tumor stage (P=0.019), lymph node metastasis (P=0.026), but no relationship with age, sex, tumor size, degree of differentiation was founded (P<0.05).
  • CONCLUSIONS: PRL-3 protein plays a novel role in tumor progression and metastasis of colorectal carcinoma.
  • PRL-3 can be expected to be a potential predictive biomarker for identifying the prognosis in colorectal carcinoma patients.
  • [MeSH-major] Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Liver Neoplasms / metabolism. Neoplasm Proteins / metabolism. Protein Tyrosine Phosphatases / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Liver Regeneration. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18803057.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Neoplasm Proteins; EC 3.1.3.48 / PTP4A3 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  •  go-up   go-down


54. Jang HS, Kang KM, Choi BO, Chai GY, Hong SC, Ha WS, Jirtle RL: Clinical significance of loss of heterozygosity for M6P/IGF2R in patients with primary hepatocellular carcinoma. World J Gastroenterol; 2008 Mar 7;14(9):1394-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of loss of heterozygosity for M6P/IGF2R in patients with primary hepatocellular carcinoma.
  • AIM: To investigate the relationship between loss of heterozygosity (LOH) for mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) and the outcomes for primary HCC patients treated with partial hepatectomy.
  • METHODS: The LOH for M6P/IGF2R in primary HCC patients was assessed using six different gene-specific nucleotide polymorphisms.
  • CONCLUSION: These results show M6P/IGF2R LOH predicts poor clinical outcomes in surgically resected primary HCC patients.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma, Hepatocellular / genetics. Liver Neoplasms / genetics. Loss of Heterozygosity / genetics. Receptor, IGF Type 2 / genetics
  • [MeSH-minor] Adult. Aged. Female. Hepatectomy. Humans. Male. Middle Aged. Polymorphism, Genetic / genetics. Predictive Value of Tests. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bioessays. 2000 Mar;22(3):274-85 [10684587.001]
  • [Cites] Oncogene. 2006 Jun 8;25(24):3463-70 [16449974.001]
  • [Cites] Bioessays. 2000 May;22(5):452-9 [10797485.001]
  • [Cites] Semin Cancer Biol. 2000 Jun;10(3):185-200 [10936068.001]
  • [Cites] Cell. 2000 Oct 27;103(3):491-500 [11081635.001]
  • [Cites] Nat Genet. 2001 Feb;27(2):153-4 [11175780.001]
  • [Cites] Exp Cell Res. 2001 Apr 1;264(2):388-96 [11262195.001]
  • [Cites] Development. 2001 May;128(10):1881-7 [11311167.001]
  • [Cites] Hum Mol Genet. 2001 Aug 15;10(17):1721-8 [11532981.001]
  • [Cites] Genes Dev. 2001 Nov 15;15(22):2917-21 [11711426.001]
  • [Cites] Hepatology. 2002 May;35(5):1153-63 [11981765.001]
  • [Cites] BMC Cancer. 2002 Jul 30;2:18 [12149131.001]
  • [Cites] Genomics. 1988 Oct;3(3):224-9 [2852162.001]
  • [Cites] Nature. 1991 Jan 3;349(6304):84-7 [1845916.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7 Suppl):1907s-1911s [8137310.001]
  • [Cites] Development. 1993 Jul;118(3):731-6 [8076514.001]
  • [Cites] Oncogene. 1995 May 4;10(9):1725-9 [7753549.001]
  • [Cites] Nat Genet. 1995 Dec;11(4):447-9 [7493029.001]
  • [Cites] Oncogene. 1996 May 2;12(9):2003-9 [8649861.001]
  • [Cites] Nat Genet. 1996 Nov;14(3):255-7 [8896552.001]
  • [Cites] Cancer Res. 1997 May 15;57(10):1851-4 [9157973.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10351-5 [9294214.001]
  • [Cites] Nature. 1997 Sep 11;389(6647):122-3 [9296483.001]
  • [Cites] Exp Cell Res. 1999 Apr 10;248(1):18-24 [10094809.001]
  • [Cites] Oncogene. 1999 Jul 15;18(28):4063-8 [10435587.001]
  • [Cites] Cell Growth Differ. 1999 Aug;10(8):591-600 [10470859.001]
  • [Cites] World J Gastroenterol. 2005 Jul 7;11(25):3850-4 [15991281.001]
  • [Cites] Oncogene. 2000 Mar 16;19(12):1572-8 [10734317.001]
  • (PMID = 18322954.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptor, IGF Type 2
  • [Other-IDs] NLM/ PMC2693688
  •  go-up   go-down


55. Wu D, Bao WG, Ding YH: [Clinical and experimental study of xiaoshui decoction in the treatment of primary liver cancer caused ascites]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2005 Dec;25(12):1066-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical and experimental study of xiaoshui decoction in the treatment of primary liver cancer caused ascites].
  • OBJECTIVE: To observe the clinical efficacy of Xiaoshui Decoction (XSD) in treating ascites in patients suffered from primary liver cancer of Pi-deficiency with damp harassment syndrome (PDDHS) as well as to study the effect through the experiment in mice.
  • METHODS: Sixty-one patients confirmed to be primary liver cancer of PDDHS and accompanied with ascites were randomly divided into the treated group (n=33) and the control group (n=28).
  • Experimental study showed that on the two mice models of ascites induced by inoculating two kinds of tumor cell, the effect of XSD was superior to that of the control group in aspects of reducing ascites and prolonging survival period, showing significant difference (P < 0.05).
  • CONCLUSION: Satisfactory short-term efficacy in treating primary liver cancer with ascites of the Pi-deficiency with damp harassment syndrome could be obtained by XSD.
  • XSD can also improve the symptoms and QOL of patients, therefore, it is an effective and reliable remedy for treatment of primary liver cancer with ascites.

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16398423.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Drugs, Chinese Herbal
  •  go-up   go-down


56. Peng N, Li L, Cai X, Tan S, Wu T: Liver stem/progenitor cells in the canals of Hering: cellular origin of hepatocellular carcinoma with bile duct tumor thrombi? Stem Cell Rev; 2010 Dec;6(4):579-84
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver stem/progenitor cells in the canals of Hering: cellular origin of hepatocellular carcinoma with bile duct tumor thrombi?
  • It is generally believed that the invasion of hepatocellular carcinoma (HCC) into the biliary tree ultimately leads to the formation of bile duct tumor thrombi (BDTT).
  • However, recent studies revealed that primary tumor might be small, even undetectable, and there was no histopathologic evidence of direct tumor invasion into bile duct wall in some patients.
  • During the last decade, efforts on stem cell biology may shed light on the pathogenesis of BDTT.
  • (1) the canals of Hering (CoH) are the most likely origin of liver stem/progenitor cells (LSPCs) in adult livers;.
  • (2) similar signalling pathways may regulate self-renewal in LSPCs and liver cancer cells, and a substantial proportion of liver tumors may often originate from the transformation of LSPCs; and (3) liver cancer contains rare cells with stem cell-like properties, which could derive from malignant transformation of LSPCs.
  • Herein, we propose that HCC with BDTT, especially with small or undetectable primary lesion and/or no histopathologic evidence for bile duct invasion, might arise from LSPCs residing in the CoH and, possibly, some primary lesions are formed firstly within the intrahepatic biliary tree.
  • When "tumor thrombi" extends mainly along bile duct, there might be "BDTT" alone; when it invades into surrounding parenchyma, there might often be small "primary tumor" with "BDTT".
  • If this holds true, the putative type may be a particular subset of HCC, and most importantly it would facilitate our understanding of stem-cell origin of HCC.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / pathology. Liver / pathology. Liver Neoplasms / pathology. Neoplastic Stem Cells / pathology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Stem Cell Rev. 2011 Nov;7(4):1046
  • (PMID = 20809255.001).
  • [ISSN] 1558-6804
  • [Journal-full-title] Stem cell reviews
  • [ISO-abbreviation] Stem Cell Rev
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


57. Olsavsky KM, Page JL, Johnson MC, Zarbl H, Strom SC, Omiecinski CJ: Gene expression profiling and differentiation assessment in primary human hepatocyte cultures, established hepatoma cell lines, and human liver tissues. Toxicol Appl Pharmacol; 2007 Jul 1;222(1):42-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling and differentiation assessment in primary human hepatocyte cultures, established hepatoma cell lines, and human liver tissues.
  • Frequently, primary hepatocytes are used as an in vitro model for the liver in vivo.
  • In this study, we characterized the differentiation character of primary human hepatocytes cultured using a highly defined, serum-free two-dimensional sandwich system, one that configures hepatocytes with collagen I as the substratum together with a dilute extracellular matrix (Matrigeltrade mark) overlay combined with a defined serum-free medium containing nanomolar levels of dexamethasone.
  • Whole genome expression profiling enabled direct comparison of liver tissues to hepatocytes and to the hepatoma-derived cell lines, HepG2 and Huh7.
  • The robustness of the primary hepatocyte cultures was reflected by the extent of unchanged expression character when compared directly to liver, with more than 77% of the probe sets unchanged in each of the over-represented categories, representing such genes as C/EBPalpha, HNF4alpha, CYP2D6, and ABCB1.
  • In contrast, HepG2 and Huh7 cells were unchanged from the liver tissues for fewer than 48% and 55% of these probe sets, respectively.
  • Further, hierarchical clustering of the hepatocytes, but not the cell lines, shifted from donor-specific to treatment-specific when the probe sets were filtered to focus on phenobarbital-inducible genes, indicative of the highly differentiated nature of the hepatocytes when cultured in a highly defined two-dimensional sandwich system.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Phenobarbital .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W645-50 [16912992.001]
  • [Cites] Toxicol In Vitro. 2002 Feb;16(1):89-99 [11812644.001]
  • [Cites] Clin Pharmacol Ther. 2000 Oct;68(4):356-66 [11061575.001]
  • [Cites] Biochem Pharmacol. 2001 May 15;61(10):1293-303 [11322933.001]
  • [Cites] Bioinformatics. 2001 Jun;17(6):509-19 [11395427.001]
  • [Cites] Toxicol Sci. 2002 Jun;67(2):219-31 [12011481.001]
  • [Cites] Xenobiotica. 2002 Jun;32(6):505-20 [12160483.001]
  • [Cites] Science. 2002 Oct 11;298(5592):422-4 [12376703.001]
  • [Cites] Toxicol Sci. 2003 Jun;73(2):386-402 [12657743.001]
  • [Cites] Mol Endocrinol. 2003 Jul;17(7):1268-82 [12663745.001]
  • [Cites] Drug Metab Dispos. 2003 Aug;31(8):1035-42 [12867492.001]
  • [Cites] Toxicol Sci. 2003 Sep;75(1):208-22 [12832660.001]
  • [Cites] Genome Res. 2003 Sep;13(9):2129-41 [12952881.001]
  • [Cites] Exp Cell Res. 2004 Jan 15;292(2):252-64 [14697333.001]
  • [Cites] Mol Pharmacol. 2004 Mar;65(3):550-7 [14978233.001]
  • [Cites] Genomics. 2004 Apr;83(4):541-9 [15028276.001]
  • [Cites] J Biol Chem. 2004 May 21;279(21):22250-7 [15004017.001]
  • [Cites] Pharm Res. 2004 Jul;21(7):1294-302 [15290872.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Apr;85(7):2161-5 [3353374.001]
  • [Cites] Arch Biochem Biophys. 1993 Feb 15;301(1):103-13 [8442654.001]
  • [Cites] Biomaterials. 1996 Feb;17(3):373-85 [8745335.001]
  • [Cites] Methods Enzymol. 1996;272:388-401 [8791798.001]
  • [Cites] Toxicol Pathol. 1996 Jan-Feb;24(1):48-57 [8839280.001]
  • [Cites] Arch Biochem Biophys. 1997 Jan 15;337(2):275-83 [9016823.001]
  • [Cites] Biochem Pharmacol. 1997 Oct 1;54(7):761-72 [9353130.001]
  • [Cites] Drug Metab Dispos. 1999 Jun;27(6):637-44 [10348791.001]
  • [Cites] Drug Metab Dispos. 1999 Aug;27(8):887-94 [10421615.001]
  • [Cites] Drug Metab Dispos. 1999 Aug;27(8):909-15 [10421618.001]
  • [Cites] J Biol Chem. 2004 Nov 19;279(47):49517-22 [15358766.001]
  • [Cites] Drug Metab Dispos. 2005 Mar;33(3):388-94 [15608134.001]
  • [Cites] Toxicol Sci. 2005 Jun;85(2):927-34 [15772367.001]
  • [Cites] BMC Genomics. 2005;6:59 [15854232.001]
  • [Cites] Reprod Toxicol. 2005 Sep-Oct;20(3):433-40 [15964738.001]
  • [Cites] Toxicology. 2006 Feb 1;218(2-3):205-15 [16337326.001]
  • [Cites] BMC Bioinformatics. 2006;7:49 [16448562.001]
  • [Cites] Mol Pharmacol. 2002 Jan;61(1):1-6 [11752199.001]
  • [Cites] BMC Bioinformatics. 2006;7:359 [16872483.001]
  • (PMID = 17512962.001).
  • [ISSN] 0041-008X
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / ES011387-02; United States / NIEHS NIH HHS / ES / U19 ES011387-05; United States / NIGMS NIH HHS / GM / R01 GM066411-03; United States / NIGMS NIH HHS / GM / R01 GM066411; United States / NIEHS NIH HHS / ES / ES011387-04; United States / NIGMS NIH HHS / GM / GM066411-01; United States / NIEHS NIH HHS / ES / U19 ES011387-05S1; United States / NIGMS NIH HHS / GM / GM066411; United States / NIEHS NIH HHS / ES / P30 ES005022; United States / NIEHS NIH HHS / ES / ES011387-01; United States / NIEHS NIH HHS / ES / U19 ES011387; United States / NIGMS NIH HHS / GM / R01 GM066411-01; United States / NIGMS NIH HHS / GM / GM066411-04; United States / NIEHS NIH HHS / ES / U19 ES011387-04; United States / NIEHS NIH HHS / ES / ES011387-03; United States / NIGMS NIH HHS / GM / R01 GM066411-02; United States / NIEHS NIH HHS / ES / U19 ES11387; United States / NIGMS NIH HHS / GM / GM066411-02; United States / NIEHS NIH HHS / ES / ES011387-05S1; United States / NIEHS NIH HHS / ES / U19 ES011387-01; United States / NIEHS NIH HHS / ES / U19 ES011387-03; United States / NIEHS NIH HHS / ES / ES011387-05; United States / NIGMS NIH HHS / GM / GM066411-03; United States / NIEHS NIH HHS / ES / U19 ES011387-02; United States / NIGMS NIH HHS / GM / R01 GM066411-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Differentiation; 0 / Biomarkers; 63231-63-0 / RNA; YQE403BP4D / Phenobarbital
  • [Other-IDs] NLM/ NIHMS243113; NLM/ PMC2974173
  •  go-up   go-down


58. Wang J, Qin Y, Li B, Sun Z, Yang B: Detection of aberrant promoter methylation of GSTP1 in the tumor and serum of Chinese human primary hepatocellular carcinoma patients. Clin Biochem; 2006 Apr;39(4):344-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of aberrant promoter methylation of GSTP1 in the tumor and serum of Chinese human primary hepatocellular carcinoma patients.
  • To explore the aberrant promoter CpG island methylation of the GSTP1 gene as a biomarker for screening hepatocellular carcinoma (HCC) high risk individuals and for the early detection of HCC, we analyzed its methylation in the tumor and non-tumor tissues and serum samples from 26 patients with HCC, as well as serum from 8 liver cirrhosis patients by methylation-specific PCR (MSP).
  • [MeSH-major] Carcinoma, Hepatocellular / enzymology. DNA Methylation. Glutathione S-Transferase pi / genetics. Liver Neoplasms / enzymology. Promoter Regions, Genetic
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16527261.001).
  • [ISSN] 0009-9120
  • [Journal-full-title] Clinical biochemistry
  • [ISO-abbreviation] Clin. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi
  •  go-up   go-down


59. Andrle J, Schartinger VH, Schwentner I, Deibl M, Sprinzl GM: Initial staging examinations for head and neck squamous cell carcinoma: are they appropriate? J Laryngol Otol; 2009 Aug;123(8):885-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial staging examinations for head and neck squamous cell carcinoma: are they appropriate?
  • OBJECTIVES: The presence of distant metastases affects the therapeutic regime in patients with head and neck squamous cell carcinoma.
  • This study evaluated the necessity to undertake bone scanning, chest computed tomography and abdominal ultrasonography in patients presenting with primary advanced head and neck squamous cell carcinoma.
  • METHODS: One hundred and sixty-three patients with head and neck squamous cell carcinoma who were scheduled for major surgery underwent screening for distant metastases.
  • Only one patient with primary liver metastases was detected by abdominal ultrasonography; this patient also had pulmonary metastases.
  • CONCLUSIONS: Computed tomography of the thorax is the most important technique for screening patients with head and neck squamous cell carcinoma.
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Squamous Cell / secondary. Head and Neck Neoplasms. Lung Neoplasms / secondary. Neoplasms, Second Primary / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone and Bones / radionuclide imaging. Female. Humans. Male. Middle Aged. Neoplasm Staging / methods. Retrospective Studies. Tomography, X-Ray Computed / methods


60. Tang TJ, Vukosavljevic D, Janssen HL, Binda RS, Mancham S, Tilanus HW, Ijzermans JN, Drexhage H, Kwekkeboom J: Aberrant composition of the dendritic cell population in hepatic lymph nodes of patients with hepatocellular carcinoma. Hum Pathol; 2006 Mar;37(3):332-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant composition of the dendritic cell population in hepatic lymph nodes of patients with hepatocellular carcinoma.
  • Patients with hepatocellular carcinoma (HCC) are characterized by a weak T-cell response to their tumor, and chronic carriers of hepatitis B virus or hepatitis C virus have a poor T-cell response against the virus.
  • These inadequate T-cell responses may be due to insufficient activation of the T cells by dendritic cells (DCs).
  • Because lymph nodes (LNs) are the primary site of antigen-specific T-cell activation, we hypothesized that hepatic LNs of patients with HCC and/or chronic viral hepatitis might have aberrant compositions of their DC populations.
  • Patients with HCC and chronic viral hepatitis and patients with chronic viral hepatitis without HCC were compared with patients with liver inflammation of nonviral etiology and with organ donors with healthy livers.
  • The numbers of PDCs and mature MDCs in hepatic LNs of patients with chronic viral hepatitis did not differ from those of patients with liver inflammation of nonviral etiology nor from individuals with healthy livers.
  • However, hepatic LNs of patients with HBV or HCV infection complicated by HCC showed a 1.5-fold reduction in numbers of mature MDCs and a 4-fold increase in numbers of PDCs in their T-cell areas compared with those of patients with viral hepatitis only (P <.01).
  • This may be one of the causes of the inadequate T-cell response against HCC in these patients.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Dendritic Cells / pathology. Hepatitis B, Chronic / pathology. Hepatitis C, Chronic / pathology. Liver Neoplasms / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Count. Child. DNA, Viral / blood. Female. Hepacivirus / genetics. Hepacivirus / isolation & purification. Hepatitis B virus / genetics. Hepatitis B virus / isolation & purification. Humans. Male. Middle Aged. RNA, Viral / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613328.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / RNA, Viral
  •  go-up   go-down


61. Park WS, Cho YG, Kim CJ, Song JH, Lee YS, Kim SY, Nam SW, Lee SH, Yoo NJ, Lee JY: Hypermethylation of the RUNX3 gene in hepatocellular carcinoma. Exp Mol Med; 2005 Aug 31;37(4):276-81
Hazardous Substances Data Bank. AZACITIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylation of the RUNX3 gene in hepatocellular carcinoma.
  • To elucidate the potential etiological role of the RUNX3 gene in the development of hepatocellular carcinoma (HCC), we have analyzed the methylation status of 5' CpG island of the RUNX3 gene in a series of 73 HCC tissues and 11 liver cell lines.
  • Expectedly, promoter methylation of RUNX3 gene was found in 2 (2.7%) of 73 corresponding normal liver, whereas 30 (41.1%) of 73 HCCs and 4 (40%) of 10 liver cancer cell lines showed hypermethylation of the gene, respectively.
  • There was no significant difference between promoter hypermethylaion and clinicopathologic parameters of primary HCC samples, including histologic grade, microvascular invasion, and clinical stage.
  • Interestingly, demethylating agent 5-aza-2-deoxycytidine induced reactivation and more potent expression of RUNX3 gene in HCC cell lines.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. DNA Methylation. DNA, Neoplasm / metabolism. Liver Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Female. Humans. Male. Middle Aged. Promoter Regions, Genetic

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16155404.001).
  • [ISSN] 1226-3613
  • [Journal-full-title] Experimental & molecular medicine
  • [ISO-abbreviation] Exp. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  •  go-up   go-down


62. Knight B, Yeap BB, Yeoh GC, Olynyk JK: Inhibition of adult liver progenitor (oval) cell growth and viability by an agonist of the peroxisome proliferator activated receptor (PPAR) family member gamma, but not alpha or delta. Carcinogenesis; 2005 Oct;26(10):1782-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of adult liver progenitor (oval) cell growth and viability by an agonist of the peroxisome proliferator activated receptor (PPAR) family member gamma, but not alpha or delta.
  • Multifaceted evidence links the development of liver tumours to the activation and proliferation of adult liver progenitor (oval) cells during the early stages of chronic liver injury.
  • The aim of this study was to examine the role of the peroxisome proliferator activated receptors (PPARs): PPARalpha, delta and gamma, in mediating the behaviour of liver progenitor cells during pre-neoplastic disease and to investigate their potential as therapeutic targets for the treatment of chronic liver injury.
  • We observed increased liver expression of PPARalpha and gamma in concert with expanding oval cell numbers during the first 21 days following commencement of the choline deficient, ethionine supplemented (CDE) dietary model of carcinogenic liver injury in mice.
  • Both primary and immortalized liver progenitor cells were found to express PPARalpha, delta and gamma, but not gamma2, the alternate splice form of PPARgamma.
  • WY14643 (PPARalpha agonist), GW501516 (PPARdelta agonist) and ciglitazone (PPARgamma agonist) were tested for their ability to modulate the behaviour of p53-immortalized liver (PIL) progenitor cell lines in vitro.
  • In contrast, the PPARalpha agonist had no effect on PIL cell growth.
  • Administration of the PPARgamma agonist ciglitazone to mice fed with the CDE diet for 14 days resulted in a significantly diminished oval cell response and decreased fibrosis compared with those receiving placebo.
  • In contrast, GW501516 did not affect oval cell numbers or liver fibrosis, but inhibited CDE-induced hepatic steatosis.
  • In summary, PPARgamma agonists reduce oval cell proliferation and fibrosis during chronic liver injury and may be useful in the prevention of hepatocellular carcinoma.
  • [MeSH-major] Ethionine / toxicity. Liver / cytology. PPAR alpha / physiology. PPAR gamma / agonists. Receptors, Cytoplasmic and Nuclear / physiology. Stem Cells / cytology
  • [MeSH-minor] Animals. Cell Division / drug effects. Cell Line. Cell Survival / drug effects. Male. Mice. Mice, Inbred C57BL. Thiazoles / pharmacology. Thiazolidinediones / pharmacology

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-ETHIONINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15917308.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GW 501516; 0 / PPAR alpha; 0 / PPAR gamma; 0 / Ppard protein, mouse; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Thiazoles; 0 / Thiazolidinediones; 74772-77-3 / ciglitazone; WX1BN24WZT / Ethionine
  •  go-up   go-down


63. Chalermchai T, Suwanrusme H, Chantranuwat P, Voravud N, Sriuranpong V: Retrospective review of extra-pulmonary small cell carcinoma at King Chulalongkorn memorial hospital cases during 1998-2005. Asia Pac J Clin Oncol; 2010 Jun;6(2):111-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective review of extra-pulmonary small cell carcinoma at King Chulalongkorn memorial hospital cases during 1998-2005.
  • OBJECTIVE: The aim of this study was to review cases of extra-pulmonary small cell carcinoma (EPSCC), including their clinical manifestations and treatment outcomes.
  • The most common primary sites were the gastrointestinal organs and the nasal cavity.
  • EPSCC of pancreas demonstrated a favorable clinical outcome with treatment, whereas primary EPSCC of the liver, esophagus and rectum had an aggressive natural history and a poor response to treatment.
  • CONCLUSION: Our report suggests that EPSCC may have a different biology from that of pulmonary small cell carcinoma.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Gastrointestinal Neoplasms / drug therapy. Gastrointestinal Neoplasms / pathology. Gastrointestinal Neoplasms / surgery. Humans. Male. Middle Aged. Neoplasms, Unknown Primary / drug therapy. Neoplasms, Unknown Primary / pathology. Neoplasms, Unknown Primary / surgery. Nose Neoplasms / drug therapy. Nose Neoplasms / pathology. Nose Neoplasms / radiotherapy. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome. Urogenital Neoplasms / drug therapy. Urogenital Neoplasms / pathology. Urogenital Neoplasms / surgery. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20565423.001).
  • [ISSN] 1743-7563
  • [Journal-full-title] Asia-Pacific journal of clinical oncology
  • [ISO-abbreviation] Asia Pac J Clin Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Number-of-references] 15
  •  go-up   go-down


64. Tangjitgamol S, Manusirivithaya S, Choomchuay N, Leelahakorn S, Thawaramara T, Pataradool K, Suekwatana P: Paclitaxel and carboplatin for large cell neuroendocrine carcinoma of the uterine cervix. J Obstet Gynaecol Res; 2007 Apr;33(2):218-24
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel and carboplatin for large cell neuroendocrine carcinoma of the uterine cervix.
  • The prognosis of large cell neuroendocrine carcinoma (LCNEC) of the uterine cervix is generally poor despite multimodality of treatments.
  • However, she subsequently had progressive diseases in the liver and brain and finally died at 44 months after primary diagnosis and 19 months after recurrent diseases.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Carcinoma, Large Cell / drug therapy. Carcinoma, Neuroendocrine / drug therapy. Paclitaxel / therapeutic use. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Agents, Phytogenic / therapeutic use. Brain Neoplasms / secondary. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Fatal Outcome. Female. Humans. Liver Neoplasms / secondary. Neoplasm Recurrence, Local. Ovariectomy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17441901.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


65. Kim KO, Lee HY, Chun SH, Shin SJ, Kim MK, Lee KH, Hyun MS, Bae SH, Ryoo HM: Clinical overview of extrapulmonary small cell carcinoma. J Korean Med Sci; 2006 Oct;21(5):833-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical overview of extrapulmonary small cell carcinoma.
  • The objective of this study was to review the natural history of extrapulmonary small cell carcinoma (EPSCC) with specific emphasis on clinical features, response to treatment and survival.
  • The primary sites of tumor were the esophagus and thymus in 6 patients (17.6%) each, pancreas and stomach in 5 patients each (14.7%); other sites included were the cervix, abdominal lymph nodes, abdominal wall, bladder, colon, maxillary sinus, nasal cavity, ovary, parotid gland and liver.
  • Independent prognostic factors included stage and primary tumor location.
  • [MeSH-major] Carcinoma, Small Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Esophageal Neoplasms / mortality. Esophageal Neoplasms / therapy. Female. Humans. Male. Middle Aged. Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / therapy. Stomach Neoplasms / mortality. Stomach Neoplasms / therapy. Survival Rate. Thymus Neoplasms / mortality. Thymus Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Jan 15;88(2):262-7 [10640955.001]
  • [Cites] Semin Respir Crit Care Med. 2005 Jun;26(3):333-41 [16052435.001]
  • [Cites] Hepatogastroenterology. 2001 Nov-Dec;48(42):1588-93 [11813580.001]
  • [Cites] Cancer. 2003 Mar 15;97(6):1436-41 [12627507.001]
  • [Cites] Tumori. 2003 May-Jun;89(3):274-7 [12908782.001]
  • [Cites] Jpn J Clin Oncol. 2004 May;34(5):250-4 [15231859.001]
  • [Cites] Am J Clin Pathol. 1982 Feb;77(2):123-36 [7064914.001]
  • [Cites] Semin Oncol. 1982 Dec;9(4):484-96 [6302908.001]
  • [Cites] Hum Pathol. 1987 Jan;18(1):9-21 [2434408.001]
  • [Cites] Am J Gastroenterol. 1987 Apr;82(4):382-5 [3031980.001]
  • [Cites] Medicine (Baltimore). 1987 Nov;66(6):457-71 [2824968.001]
  • [Cites] Cancer. 1989 Oct 1;64(7):1531-3 [2550125.001]
  • [Cites] Med Pediatr Oncol. 1992;20(2):89-99 [1310345.001]
  • [Cites] Chest. 1995 Jan;107(1):179-81 [7813272.001]
  • [Cites] Ann Oncol. 1994 Dec;5(10):909-13 [7696162.001]
  • [Cites] Acta Oncol. 1997;36(1):78-80 [9090972.001]
  • [Cites] Cancer. 1997 May 1;79(9):1729-36 [9128989.001]
  • [Cites] Cancer. 1997 Oct 15;80(8):1366-72 [9338459.001]
  • [Cites] South Med J. 2005 Mar;98(3):345-9 [15813162.001]
  • [Cites] Int J Gynecol Cancer. 2005 Mar-Apr;15(2):295-300 [15823115.001]
  • [Cites] Neth J Med. 2000 Feb;56(2):51-5 [10710941.001]
  • (PMID = 17043415.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2721992
  •  go-up   go-down


66. Lin GH, Wang J, Li SH, Wang J, Xu L, Li SP: Relationship and clinical significance of TGF-beta1 expression with Treg cell infiltration in hepatocellular carcinoma. Chin J Cancer; 2010 Apr;29(4):403-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship and clinical significance of TGF-beta1 expression with Treg cell infiltration in hepatocellular carcinoma.
  • BACKGROUND AND OBJECTIVE: There are few studies about origins of regulatory T (Treg) cells increased in primary hepatocellular carcinoma (HCC) tissue.
  • Studies showed that Treg cells could be induced by transforming growth factor-beta1 (TGF-beta1), but the relation between TGF-beta1 expression and Treg cell infiltration is unclear in HCC tissue.
  • METHODS: Envision immunohistochemistry was used to detect the expression of TGF-beta1 and Foxp3 in 102 specimens of HCC tissue and paired adjacent non-tumor liver tissue.
  • Average Foxp3+ cell density in HCC was 2.98 cells/HP, but there was very few or no expression of Foxp3 in adjacent non-tumor liver tissue.
  • TGF-beta1 and Foxp3 expression had no correlations with tumor diameter, tumor capsule, liver cirrhosis, and so on.
  • The 5-year survival rate was not different between HCC tissues with high and low TGF-beta1 expression (P = 0.790); however, it was significantly lower in HCC tissues with high Treg cell infiltration than in those low infiltration (25% vs. 44%, P = 0.007).
  • [MeSH-major] Carcinoma, Hepatocellular. Liver Neoplasms. T-Lymphocytes, Regulatory / pathology. Transforming Growth Factor beta1 / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Forkhead Transcription Factors / metabolism. Humans. Lymphocyte Count. Male. Middle Aged. Neoplasm Invasiveness. Proportional Hazards Models. Survival Rate. Young Adult. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20346216.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Transforming Growth Factor beta1; 0 / alpha-Fetoproteins
  •  go-up   go-down


67. Pan HW, Chou HY, Liu SH, Peng SY, Liu CL, Hsu HC: Role of L2DTL, cell cycle-regulated nuclear and centrosome protein, in aggressive hepatocellular carcinoma. Cell Cycle; 2006 Nov;5(22):2676-87
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of L2DTL, cell cycle-regulated nuclear and centrosome protein, in aggressive hepatocellular carcinoma.
  • This study is to elucidate its function and clinicopathological significance in hepatocellular carcinoma (HCC) progression.
  • We used RT-PCR, immunostaining, Western blotting, and centrosome isolation to determine the L2DTL expression and protein localization, and RNAi to analyze its role in tumor cell growth.
  • L2DTL protein located to the nucleus in interphase and centered to centrosomes, with colocalization of gamma-tubulin and Aurora-A, throughout the cell cycle, and cofractionated with gamma-tubulin.
  • L2DTL gene expression increased during G1/S phase, and the DNA synthesis in liver regeneration.
  • L2DTL downregulation by RNAi oligos led to reduced cancer cell growth and invasion capability in vitro, in which microarray analysis disclosed dysregulation of genes involved in cell cycle regulation, chromosome segregation, and cell division.
  • L2DTL overexpressed in 59% of 270 resected, unifocal, primary HCCs.
  • In conclusion, L2DTL encodes a nuclear protein with centrosome targeting in mitosis, and plays important roles in DNA synthesis, cell cycle progression, cytokinesis, proliferation, and differentiation.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / physiology. Carcinoma, Hepatocellular / metabolism. Cell Cycle. Centrosome / metabolism. Liver Neoplasms / metabolism. Nuclear Proteins / physiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cadherins / metabolism. Down-Regulation. HeLa Cells. Humans. Middle Aged. RNA, Messenger / metabolism. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism. Ubiquitin-Protein Ligases

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17106265.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / CDH1 protein, human; 0 / Cadherins; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / DTL protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


68. Cassiman D, Libbrecht L, Verslype C, Meersseman W, Troisi R, Zucman-Rossi J, Van Vlierberghe H: An adult male patient with multiple adenomas and a hepatocellular carcinoma: mild glycogen storage disease type Ia. J Hepatol; 2010 Jul;53(1):213-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An adult male patient with multiple adenomas and a hepatocellular carcinoma: mild glycogen storage disease type Ia.
  • The development of hepatocellular adenomas and - more rarely - carcinoma in the liver of patients with Glycogen Storage Disease type Ia (GSDIa) is a well-known complication of the disease.
  • The pathophysiology of adenoma and carcinoma development in these patients is, however, hitherto largely unknown and is thought to be related to the metabolic control of the patient and/or the type of mutations in the G6PC gene.
  • We report here on a very illustrative case of adenoma and carcinoma formation in a previously undiagnosed 42 year old male GSDIa patient (enzymatically and genetically proven).
  • He was a long-distance runner for most of his adult life, without the need for more than normal carbohydrate intake before/during exertion.
  • We show here that in this patient with mild GSDIa without recurrent hypoglycaemic episodes, adenoma and carcinoma formation still occurred and that malignant transformation of adenoma here is associated with CTNNB1 mutations and a typical mRNA profile of a beta-catenin activated lesion.
  • [MeSH-major] Adenoma, Liver Cell / etiology. Carcinoma, Hepatocellular / etiology. Glycogen Storage Disease Type I / complications. Liver Neoplasms / etiology. Neoplasms, Multiple Primary / etiology
  • [MeSH-minor] Adult. Glucose-6-Phosphatase / genetics. Humans. Male. Mutation. RNA, Messenger / genetics. RNA, Neoplasm / genetics. beta Catenin / genetics

  • Genetic Alliance. consumer health - Glycogen Storage Disease.
  • Genetic Alliance. consumer health - Hepatocellular carcinoma, adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20447711.001).
  • [ISSN] 1600-0641
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / beta Catenin; EC 3.1.3.9 / Glucose-6-Phosphatase
  •  go-up   go-down


69. Tang DJ, Dong SS, Ma NF, Xie D, Chen L, Fu L, Lau SH, Li Y, Li Y, Guan XY: Overexpression of eukaryotic initiation factor 5A2 enhances cell motility and promotes tumor metastasis in hepatocellular carcinoma. Hepatology; 2010 Apr;51(4):1255-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of eukaryotic initiation factor 5A2 enhances cell motility and promotes tumor metastasis in hepatocellular carcinoma.
  • A high incidence of tumor recurrence and metastasis has been reported in hepatocellular carcinoma (HCC) patients; however, the underlying molecular mechanisms are largely unknown.
  • Overexpression of EIF5A2 messenger RNA (mRNA) was detected in 50/81 (61.7%) of HCCs, which was significantly higher than those in nontumorous liver tissues.
  • Compared with matched primary HCC, higher expression of EIF5A2 protein was observed in 25/47 (53.2%) of metastatic tumors.
  • Functional studies found that ectopic expression of EIF5A2 could enhance cancer cell migration and invasion in vitro and tumor metastasis in vivo in an experimental mouse model.
  • Moreover, inhibition of EIF5A by small interfering RNA (siRNA) or deoxyhypusine synthase (DHPS) inhibitor GC7, which inhibits EIF5A2 maturation, could effectively decrease cell motility.
  • [MeSH-major] Carcinoma, Hepatocellular / secondary. Liver Neoplasms / pathology. Peptide Initiation Factors / physiology
  • [MeSH-minor] Adult. Aged. Animals. Cell Movement. Epithelial Cells / pathology. Female. Guanine / analogs & derivatives. Guanine / pharmacology. Humans. Male. Mesoderm / pathology. Mice. Middle Aged. Oxidoreductases Acting on CH-NH Group Donors / antagonists & inhibitors. Oxidoreductases Acting on CH-NH Group Donors / genetics. RNA, Small Interfering / genetics. rho GTP-Binding Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. GUANINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20112425.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / N(1)-guanyl-1,7-diaminoheptane; 0 / Peptide Initiation Factors; 0 / RNA, Small Interfering; 0 / eIF-5A2; 5Z93L87A1R / Guanine; EC 1.5.- / Oxidoreductases Acting on CH-NH Group Donors; EC 1.5.1.- / deoxyhypusine synthase; EC 3.6.5.2 / rho GTP-Binding Proteins
  •  go-up   go-down


70. Perera GK, Child FJ, Heaton N, O'Grady J, Higgins EM: Skin lesions in adult liver transplant recipients: a study of 100 consecutive patients. Br J Dermatol; 2006 May;154(5):868-72
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin lesions in adult liver transplant recipients: a study of 100 consecutive patients.
  • OBJECTIVES: The primary objective was to determine the different types of cutaneous lesions encountered in the adult liver transplant population.
  • METHODS: Two dermatologists examined 100 consecutive liver transplant recipients (LTRs) attending the transplant outpatient department.
  • Four patients developed skin cancers; among them there were a total of seven skin cancers (one squamous cell carcinoma, six basal cell carcinomas).
  • The relatively low prevalence of skin cancer in our liver transplant population may in part be explained by the relatively high percentage of recipients on dual and monotherapy (48% and 17% respectively), and the shorter duration of therapy.
  • [MeSH-major] Liver Transplantation / immunology. Skin Diseases / etiology
  • [MeSH-minor] Adult. Carcinoma, Basal Cell / etiology. Carcinoma, Basal Cell / immunology. Carcinoma, Squamous Cell / immunology. Carcinoma, Squamous Cell / radiotherapy. Female. Humans. Immunocompromised Host. Immunosuppressive Agents / adverse effects. Keratosis / etiology. Keratosis / immunology. Liver Failure / etiology. Liver Failure / surgery. Male. Middle Aged. Risk Factors. Skin Diseases, Infectious / etiology. Skin Diseases, Infectious / immunology. Skin Neoplasms / etiology. Skin Neoplasms / immunology. Sunlight / adverse effects

  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16634888.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


71. Jing Z, Nan KJ, Hu ML: Cell proliferation, apoptosis and the related regulators p27, p53 expression in hepatocellular carcinoma. World J Gastroenterol; 2005 Apr 7;11(13):1910-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell proliferation, apoptosis and the related regulators p27, p53 expression in hepatocellular carcinoma.
  • AIM: To investigate the expression of cell apoptosis, proliferation and the related regulators p27, p53 in hepatocellular carcinoma (HCC).
  • METHODS: The expression of p27, p53, proliferating cell nuclear antigen (PCNA) and apoptosis in 47 HCC specimens and 42 surrounding non-cancerous tissues were detected by the immunohistochemistry and terminal deoxy-nucleotidyl transferase-mediated nick end labeling (TUNEL) technique.
  • (1) The average proliferating index and apoptotic index in HCC were significantly higher than that in adjacent liver tissues.
  • (2) The level of p27 in the cytoplasmic fraction was higher in non-tumoral liver tissues and was associated with clinical stage;.
  • The combined examination of p27, and p53 expression allows reliable estimation of prognosis for patients with primary hepatic carcinoma.
  • [MeSH-major] Apoptosis / physiology. Carcinoma, Hepatocellular / metabolism. Cell Cycle Proteins / metabolism. Liver Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Cell Division / physiology. Cyclin-Dependent Kinase Inhibitor p27. Female. Humans. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15800979.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  • [Other-IDs] NLM/ PMC4305710
  •  go-up   go-down


72. Mancini V, Battaglia M, Lucarelli G, Di Lorenzo V, Ditonno P, Bettocchi C, Selvaggi FP: Unusual solitary metastasis of the ciliary body in renal cell carcinoma. Int J Urol; 2008 Apr;15(4):363-5
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual solitary metastasis of the ciliary body in renal cell carcinoma.
  • Renal cell carcinoma (RCC) usually metastasizes to the lung, liver, bone; ocular metastasis is uncommon.
  • Ocular metastasis of RCC is rare, can appear years after treating the primary tumor and should not be excluded in RCC follow-up.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Ciliary Body / pathology. Kidney Neoplasms / pathology. Uveal Neoplasms / secondary
  • [MeSH-minor] Adult. Humans. Male

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18380830.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


73. Khoshbaten M, Naderpour M, Mohammadi G, Alipoor SH, Estakhri R, Fazeli Z: Epidemiology of esophageal lesions in patients with head and neck squamous cell carcinoma. Asian Pac J Cancer Prev; 2010;11(4):863-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of esophageal lesions in patients with head and neck squamous cell carcinoma.
  • BACKGROUND: Esophageal squamous cell carcinoma (ESCC) is disturbing because of its aggressive clinical path and high mortality rate.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Esophageal Neoplasms / epidemiology. Esophagitis / epidemiology. Head and Neck Neoplasms / epidemiology. Neoplasms, Multiple Primary / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Alcohol Drinking. Coloring Agents. Esophagoscopy. Female. Humans. Iodides. Iran. Male. Middle Aged. Risk Factors. Smoking

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21133592.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / Iodides; T66M6Y3KSA / Lugol's solution
  •  go-up   go-down


74. Choi HN, Kim KR, Lee JH, Park HS, Jang KY, Chung MJ, Hwang SE, Yu HC, Moon WS: Serum response factor enhances liver metastasis of colorectal carcinoma via alteration of the E-cadherin/beta-catenin complex. Oncol Rep; 2009 Jan;21(1):57-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum response factor enhances liver metastasis of colorectal carcinoma via alteration of the E-cadherin/beta-catenin complex.
  • Serum response factor (SRF) is a transcription factor that controls cell growth, differentiation, and tumor progression as well as muscle development and function.
  • Reduced expression of cell adhesion molecules has been reported to be associated with tumor metastasis.
  • The aim of this study was to evaluate the expression and a role of SRF in liver metastasis of primary colorectal carcinomas.
  • We examined the expression of SRF, E-cadherin, and beta-catenin by the use of immunochemical staining in 43 cases as a set of primary colorectal carcinomas and liver metastases.
  • We also examined the role of SRF in colorectal carcinoma by overexpression of SRF in a colon cancer cell line.
  • In metastatic carcinoma surgical samples, there was a marked increased expression of SRF as compared to expression in primary colorectal carcinoma surgical samples (P<0.05).
  • E-cadherin expression was significantly decreased in metastatic liver carcinoma samples as compared to primary colorectal carcinoma samples (P<0.001).
  • Frequent nuclear translocation of beta-catenin protein in primary and metastatic carcinoma cells was observed.
  • Overexpression of SRF in colorectal carcinoma cells enhanced cell motility and invasiveness.
  • These results indicate that overexpression of SRF in colorectal carcinoma cells is associated with modulation of E-cadherin/beta-catenin expression and may play an important role in colorectal cancer metastasis.
  • [MeSH-major] Cadherins / metabolism. Colorectal Neoplasms / pathology. Liver Neoplasms / secondary. Serum Response Factor / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Blotting, Western. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Male. Middle Aged. Transfection

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19082443.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Serum Response Factor; 0 / beta Catenin
  •  go-up   go-down


75. Zhang Q, Ying J, Zhang K, Li H, Ng KM, Zhao Y, He Q, Yang X, Xin D, Liao SK, Tao Q, Jin J: Aberrant methylation of the 8p22 tumor suppressor gene DLC1 in renal cell carcinoma. Cancer Lett; 2007 May 8;249(2):220-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant methylation of the 8p22 tumor suppressor gene DLC1 in renal cell carcinoma.
  • Epigenetic mechanisms involving DNA methylation and chromatin remodeling are important in silencing tumor suppressor genes (TSG) in various malignancies, including renal cell carcinoma (RCC).
  • DLC1 (deleted in liver cancer 1)/ARHGAP7 is a recently identified 8p22 candidate TSG.
  • We examined DLC1 promoter methylation in 34 primary RCCs and the corresponding non-malignant tissues, and the correlation of DLC1 methylation with the clinicopathological characteristics of RCC patients.
  • Although DLC1 methylation and downregulation were only detected in one of seven RCC cell lines using methylation-specific PCR (MSP) and semi-quantitative reverse-transcription PCR, we found that the DLC1 promoter was methylated in 35% (12/34) of primary RCC tumors, which was further confirmed by direct sequencing of MSP products and high-resolution bisulfite genomic sequencing.
  • [MeSH-major] Carcinoma, Renal Cell / genetics. DNA Methylation. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / genetics. Cell Line, Tumor. Female. GTPase-Activating Proteins. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17029774.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DLC1 protein, human; 0 / GTPase-Activating Proteins; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


76. Kats-Ugurlu G, Roodink I, de Weijert M, Tiemessen D, Maass C, Verrijp K, van der Laak J, de Waal R, Mulders P, Oosterwijk E, Leenders W: Circulating tumour tissue fragments in patients with pulmonary metastasis of clear cell renal cell carcinoma. J Pathol; 2009 Nov;219(3):287-93
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating tumour tissue fragments in patients with pulmonary metastasis of clear cell renal cell carcinoma.
  • However, the high incidence of metastasis from various tumour types in liver and lung may be explained by a stochastic process as well, based on the anatomical relationship of the primary tumour with the circulation and mechanical entrapment of metastatic tumour cells in capillary beds.
  • Here we tested whether this process has clinical relevance for clear cell renal cell carcinoma (ccRCC), a prototype tumour in the sense of high constitutive VEGF-A expression.
  • In patients with tumours that, in retrospect, were not of the VEGF-A-expressing clear cell type, tumour fragments were never observed in the renal outflow.
  • These data suggest that, in ccRCC, a VEGF-A-induced phenotype promotes a release of tumour cell clusters into the circulation that may contribute to pulmonary metastasis.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Lung Neoplasms / secondary. Neoplastic Cells, Circulating / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Proteins / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • Genetic Alliance. consumer health - Clear Cell Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Pathol. 2009 Nov;219(3):275-6 [19768739.001]
  • (PMID = 19731255.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


77. Basile J, Caldwell S, Nolan N, Hammerle C: Clear cell hepatocellular carcinoma arising 25 years after the successful treatment of an infantile hepatoblastoma. Ann Hepatol; 2010 Oct-Dec;9(4):465-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell hepatocellular carcinoma arising 25 years after the successful treatment of an infantile hepatoblastoma.
  • Primary liver tumors in children are rare with hepatoblastoma (HB) being the most common malignancy.
  • Clear cell carcinoma, a variant of hepatocellular carcinoma (HCC), is another rare tumor of the liver that tends to affect adults.
  • We describe the diagnosis and management of the only known documented case of a primary clear cell HCC arising twenty-five years after the patient was successfully treated with chemotherapy and surgical resection for a malignant HB as an infant.
  • Further knowledge of liver tumorigenesis will help elucidate the complicated genetic, molecular, and environmental factors involved in the development of these two rare hepatic malignancies.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Hepatoblastoma / drug therapy. Hepatoblastoma / surgery. Liver Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biopsy. Combined Modality Therapy. Genetic Predisposition to Disease / genetics. Humans. Magnetic Resonance Imaging. Male. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatoblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21057168.001).
  • [ISSN] 1665-2681
  • [Journal-full-title] Annals of hepatology
  • [ISO-abbreviation] Ann Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


78. Mohan V, Jones RC, Drake AJ 3rd, Daly PL, Shakir KM: Littoral cell angioma presenting as metastatic thyroid carcinoma to the spleen. Thyroid; 2005 Feb;15(2):170-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Littoral cell angioma presenting as metastatic thyroid carcinoma to the spleen.
  • Papillary thyroid carcinoma (PTC) commonly metastasizes to cervical lymph nodes.
  • Well-differentiated thyroid carcinoma very rarely presents with metastases to the spleen.
  • This is the case of a 25-year-old man with a history of PTC (1.4 cm primary; no capsular invasion and negative lymph node metastases).
  • Contrast CT of the abdomen showed multiple low-attenuated heterogeneously enhancing splenic masses, normal liver and no intra-abdominal lymphadenopathy.
  • Despite the serum thyroglobulin of only 9.4 ng/mL, the finding of I(131) accumulation within solid splenic masses led to a preoperative diagnosis of thyroid carcinoma metastases.
  • Histopathologic analysis showed large littoral cell angiomas (LCA).
  • To our knowledge, this is the first case that describes multiple angiomas mimicking metastatic thyroid carcinoma to the spleen.
  • This is the first report of an association between LCA and thyroid carcinoma.
  • [MeSH-major] Carcinoma, Papillary / secondary. Hemangioma / pathology. Splenic Neoplasms / secondary. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. False Positive Reactions. Female. Humans. Iodine Radioisotopes. Tomography, X-Ray Computed. Ultrasonography, Doppler

  • Genetic Alliance. consumer health - Angioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15753678.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


79. Fu XM, Yang QX, Shao CK, Feng ZY: [Expressions of h-TERT, c-myc, PCNA and cell apoptosis in liver carcinogenesis]. Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jun;26(6):821-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expressions of h-TERT, c-myc, PCNA and cell apoptosis in liver carcinogenesis].
  • OBJECTIVE: To investigate the expressions of human telomerase reverse transcriptase (h-TERT), c-myc, and proliferating cell nuclear antigen (PCNA) in chronic viral hepatitis (CVH), liver cirrhosis and primary hepatocellular carcinoma (HCC) and understand their possible role in liver carcinogenesis.
  • METHODS: Totally 157 liver disease specimens were collected, including 56 CVH, 52 liver cirrhosis and 49 primary HCC specimens.
  • In situ hybridization was performed on these specimens to examine the expressions of h-TRET and c-myc mRNA, and immunohistochemistry carried out for PCNA detection, with the cell apoptosis detected with in situ ending labeling.
  • RESULTS: In the CVH, liver cirrhosis and primary HCC specimens, h-TERT expression was detected at the frequencies of 11/56 (19.6%), 43/52 (82.7%) and 44/47 (93.6%), c-myc expression at 7/56 (12.5%), 21/52 (40.4%) and 26/47 (55.3%), with apoptotic index of (27.3-/+4.7)%, (16.5-/+2.6)% and (8.7-/+1.3)% and PCNA expression rate of (17.1-/+2.9)%, (49.3-/+7.8)% and (62.5-/+9.1)%, respectively.
  • CONCLUSION: Liver carcinogenesis may involve increased h-TERT, c-myc, and PCNA expressions and suppressed cell apoptosis.
  • [MeSH-major] Apoptosis. Liver Neoplasms / pathology. Proliferating Cell Nuclear Antigen / biosynthesis. Proto-Oncogene Proteins c-myc / genetics. Telomerase / genetics
  • [MeSH-minor] Adult. Carcinoma, Hepatocellular / genetics. Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Cell Transformation, Neoplastic. Female. Hepatitis B, Chronic / genetics. Hepatitis B, Chronic / metabolism. Hepatitis B, Chronic / pathology. Humans. Immunohistochemistry. Liver Cirrhosis / genetics. Liver Cirrhosis / metabolism. Liver Cirrhosis / pathology. Male. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793609.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen; 0 / Proto-Oncogene Proteins c-myc; 0 / RNA, Messenger; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


80. Rivera L, Giap H, Miller W, Fisher J, Hillebrand DJ, Marsh C, Schaffer RL: Hepatic intra-arterial infusion of yttrium-90 microspheres in the treatment of recurrent hepatocellular carcinoma after liver transplantation: a case report. World J Gastroenterol; 2006 Sep 21;12(35):5729-32
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic intra-arterial infusion of yttrium-90 microspheres in the treatment of recurrent hepatocellular carcinoma after liver transplantation: a case report.
  • Hepatocellular carcinoma (HCC) recurs with a reported frequency of 12%-18% after liver transplantation.
  • Approximately one-third of recurrences develop in the transplanted liver and are therefore amenable to local therapy.
  • Yttrium-90 microspheres have been used as a treatment modality both for primary HCC and for pre-transplant management of HCC with promising results.
  • Twenty-two months after liver transplantation for hepatitis C cirrhosis complicated by HCC, a 42-year old man developed recurrence of HCC in his transplant allograft.
  • Multifocal recurrence in the remaining liver allograft was treated with hepatic intra-arterial infusion of yttrium-90 microspheres (SIR-Spheres, Sirtex Medical Inc., Lake Forest, IL, USA).
  • [MeSH-major] Carcinoma, Hepatocellular / radiotherapy. Liver Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Yttrium Radioisotopes / therapeutic use
  • [MeSH-minor] Adult. Hepatitis C. Humans. Infusions, Intra-Arterial. Liver Transplantation. Male. Microspheres. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Mar 15;94(6):1747-52 [11920537.001]
  • [Cites] J Vasc Interv Radiol. 2002 Sep;13(9 Pt 2):S223-9 [12354840.001]
  • [Cites] Transplantation. 2002 Dec 27;74(12):1746-51 [12499891.001]
  • [Cites] Liver Transpl. 2004 Feb;10(2 Suppl 1):S107-10 [14762849.001]
  • [Cites] Psychooncology. 2004 Feb;13(2):73-9 [14872525.001]
  • [Cites] Liver Transpl. 2005 Sep;11(9):1127-31 [16123954.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):693-9 [8594428.001]
  • [Cites] J Vasc Interv Radiol. 2005 Feb;16(2 Pt 1):195-203 [15713920.001]
  • [Cites] J Vasc Interv Radiol. 2005 Feb;16(2 Pt 1):205-13 [15713921.001]
  • [Cites] Arch Surg. 2005 Apr;140(4):353-8 [15837885.001]
  • [Cites] Liver Transpl. 2004 Apr;10(4):534-40 [15048797.001]
  • (PMID = 17007031.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Yttrium Radioisotopes
  • [Other-IDs] NLM/ PMC4088179
  •  go-up   go-down


81. Krstevska V, Stojkovski I, Zafirova-Ivanova B: Factors influencing the development of distant metastases in patients with head and neck squamous cell carcinoma. J BUON; 2010 Oct-Dec;15(4):690-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors influencing the development of distant metastases in patients with head and neck squamous cell carcinoma.
  • PURPOSE: the aim of this retrospective study was to evaluate the frequency of distant metastases (DM) and to define factors that influence DM free survival (DMFS) in patients with head and neck squamous cell carcinoma (HNSCC).
  • METHODS: the charts of 201 patients with oral cavity, pharyngeal, or laryngeal carcinoma, treated with postoperative radiotherapy (RT) or definitive RT between 1999 and 2004 and achieved locoregional control were analyzed.
  • Univariate analysis demonstrated that the risk of DM was significantly influenced by age (p=0.047), cigarette smoking (p=0.024), ECOG performance status (PS) (p=0.008), location of the primary site (p=0.003), N stage (p<0.0001), overall stage (p<0.0001), histological differentiation (p<0.0001), levels of nodal involvement (p<0.0001), treatment modality (p<0.0002), presence of locoregional recurrence (LRR) (p<0.0001), and time to LRR (p<0.0001).
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Squamous Cell / secondary. Head and Neck Neoplasms / pathology. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Prognosis. Radiotherapy Dosage. Retrospective Studies. Survival Rate


82. Kim H, Oh BK, Roncalli M, Park C, Yoon SM, Yoo JE, Park YN: Large liver cell change in hepatitis B virus-related liver cirrhosis. Hepatology; 2009 Sep;50(3):752-62
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large liver cell change in hepatitis B virus-related liver cirrhosis.
  • Large liver cell change (LLCC) refers to microscopic lesions often found in various chronic liver diseases; however, its nature is still controversial.
  • Thirty-four formalin-fixed and 19 fresh frozen hepatitis B virus (HBV)-related cirrhosis samples were examined for the presence of LLCC, small liver cell change (SLCC), and hepatocellular carcinoma (HCC).
  • The cell cycle checkpoint status (p21, p27, p16, Tp53), cell dynamics (proliferating cell nuclear antigen, Ki-67, terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling, M30), DNA damage (gamma-H2AX [H2A histone family, member X]), telomere lengths, chromosomal instability (micronuclei index), and senescence-associated beta-galactosidase (SA-beta-Gal) activity were evaluated using an in situ approach and compared to those in normal liver (n = 5) and liver with chronic cholestasis (34 cases of hepatolithiasis and three cases of primary biliary cirrhosis).
  • In HBV-related cirrhosis, the p21, p27, and p16 cell cycle checkpoint markers were activated in normal-looking cirrhotic hepatocytes (NLCH), but diminished gradually from LLCC, SLCC, to HCC, with an increase in Tp53 expression.
  • In contrast, cholestatic LLCC showed retained expression of cell cycle checkpoint markers and decreased net cellular gain compared to adjacent normal-looking hepatocytes.
  • The characteristics of HBV-related LLCC are more consistent with dysplastic rather than merely reactive hepatocytes, whereas cholestatic LLCC more likely represents reactive change with more stringent cell cycle checkpoint control.
  • [MeSH-major] Hepatitis B, Chronic / pathology. Liver Cirrhosis / pathology
  • [MeSH-minor] Adult. Aged. Apoptosis. Carcinoma, Hepatocellular / pathology. Cell Aging / physiology. Cell Cycle. Cell Proliferation. Cholestasis, Intrahepatic / metabolism. Cholestasis, Intrahepatic / pathology. Chromosomal Instability. DNA Damage. Female. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Liver Neoplasms / pathology. Middle Aged. Telomere / chemistry. beta-Galactosidase / analysis

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19585549.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.2.1.23 / beta-Galactosidase
  •  go-up   go-down


83. Kikkawa Y, Sudo R, Kon J, Mizuguchi T, Nomizu M, Hirata K, Mitaka T: Laminin alpha 5 mediates ectopic adhesion of hepatocellular carcinoma through integrins and/or Lutheran/basal cell adhesion molecule. Exp Cell Res; 2008 Aug 15;314(14):2579-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laminin alpha 5 mediates ectopic adhesion of hepatocellular carcinoma through integrins and/or Lutheran/basal cell adhesion molecule.
  • Little is known, however, about the expression and function of laminins containing the alpha 5 chain in human hepatocellular carcinoma (HCC).
  • Here, using a specific antibody, we examined the expression of laminin alpha 5 in normal liver and in HCCs.
  • In normal liver, although laminin alpha 5 was observed in hepatic BLs underlying blood vessels and bile ducts, it was absent from the parenchyma, which may be the origin of HCC.
  • In HCC cell lines, laminin alpha 5 heterotrimerized with beta and gamma chains and was secreted into the culture media.
  • In this regard, alpha 3 beta 1/alpha 6 beta 1 integrins and Lutheran/basal cell adhesion molecule (Lu/B-CAM) were expressed in HCC cells.
  • In vitro studies showed that HCC cells readily attached to laminin containing the alpha 5 chain, more so than did primary hepatocytes.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Cell Adhesion Molecules / metabolism. Integrins / metabolism. Laminin / metabolism. Liver Neoplasms / pathology. Neoplasm Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Animals. Cell Adhesion. Female. Humans. Immunohistochemistry. Integrin alpha6beta4 / metabolism. Liver / metabolism. Lutheran Blood-Group System. Male. Middle Aged. Protein Transport. Rats. Rats, Sprague-Dawley

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18635166.001).
  • [ISSN] 1090-2422
  • [Journal-full-title] Experimental cell research
  • [ISO-abbreviation] Exp. Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCAM protein, human; 0 / Cell Adhesion Molecules; 0 / Integrin alpha6beta4; 0 / Integrins; 0 / Laminin; 0 / Lutheran Blood-Group System; 0 / Neoplasm Proteins; 0 / laminin alpha5
  •  go-up   go-down


84. Ding T, Xu J, Wang F, Shi M, Zhang Y, Li SP, Zheng L: High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. Hum Pathol; 2009 Mar;40(3):381-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection.
  • This study attempted to investigate the prognostic values of tumor-infiltrating macrophages in patients with hepatocellular carcinoma after resection, paying particular attention to their tissue microlocalization.
  • The CD68(+) macrophages were assessed by immunohistochemistry in tissues from 137 patients with hepatocellular carcinoma.
  • Our results demonstrate that high macrophage infiltration predicts poor prognosis in patients with hepatocellular carcinoma.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Macrophages / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Cell Count. Cell Line, Tumor. Cell Movement. Disease-Free Survival. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Prognosis. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18992916.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human
  •  go-up   go-down


85. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarbá JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE: Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol; 2010 Feb 20;28(6):1061-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.
  • This randomized, double-blind, placebo-controlled phase III study evaluated efficacy and safety of pazopanib monotherapy in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC).
  • PATIENTS AND METHODS Adult patients with measurable, locally advanced, and/or metastatic RCC were randomly assigned 2:1 to receive oral pazopanib or placebo.
  • The primary end point was progression-free survival (PFS).
  • [MeSH-major] Bone Neoplasms / drug therapy. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Pyrimidines / therapeutic use. Sulfonamides / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Double-Blind Method. Female. Humans. International Agencies. Male. Middle Aged. Neoplasm Staging. Placebos. Prognosis. Survival Rate. Treatment Outcome. Young Adult


86. Kannangai R, Sahin F, Torbenson MS: EGFR is phosphorylated at Ty845 in hepatocellular carcinoma. Mod Pathol; 2006 Nov;19(11):1456-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR is phosphorylated at Ty845 in hepatocellular carcinoma.
  • Epidermal growth factor receptor (EGFR) is overexpressed in a significant proportion of hepatocellular carcinomas.
  • Recent studies of EGFR inhibitors to treat hepatocellular carcinoma have been encouraging and better understanding of EGFR signaling may lead to more effective strategies for inhibiting this key pathway.
  • Cell line and animal studies have shown that MAPK and STAT-3 are important mediators of the EGFR signal in liver cells.
  • However, little is known about EGFR phosphorylation and subsequent signaling in primary hepatocellular carcinoma.
  • We investigated the site of EGFR phosphorylation by Western blot in 18 hepatocellular carcinomas.
  • Fourteen of 18 hepatocellular carcinomas had detectable EGFR by Western blotting and 13 of 14 showed phosphorylation at tyrosine 845.
  • These findings were further explored by examination of EGFR expression and signaling pathway activation in tissue arrays comprised of 73 hepatocellular carcinomas using antibodies that recognize phosphorylated (or activated) proteins.
  • We conclude that EGFR is phosphorylated at tyrosine 845 in most hepatocellular carcinomas and that EGFR expression by immunohistochemistry does not correlate well with STAT-3, STAT-5, MAPK, or AKT immunostaining.
  • [MeSH-major] Carcinoma, Hepatocellular / chemistry. Liver Neoplasms / chemistry. Receptor, Epidermal Growth Factor / analysis. Tyrosine / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Line, Tumor. Cell Proliferation. Child. Female. Humans. Immunohistochemistry. Male. Middle Aged. Mitogen-Activated Protein Kinase 1 / analysis. Mitogen-Activated Protein Kinase 3 / analysis. Phosphorylation. Proto-Oncogene Proteins c-akt / analysis. STAT3 Transcription Factor / analysis. STAT5 Transcription Factor / analysis. Signal Transduction. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. L-TYROSINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16936701.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / STAT5 Transcription Factor; 42HK56048U / Tyrosine; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  •  go-up   go-down


87. Sandhu SS, Symes A, A'Hern R, Sohaib SA, Eisen T, Gore M, Christmas TJ: Surgical excision of isolated renal-bed recurrence after radical nephrectomy for renal cell carcinoma. BJU Int; 2005 Mar;95(4):522-5
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical excision of isolated renal-bed recurrence after radical nephrectomy for renal cell carcinoma.
  • OBJECTIVE: To present our results on managing loco-regional recurrence of renal cell carcinoma (RCC) with surgical excision, as local recurrence at the site of a previous nephrectomy is resistant to both systemic therapy and radiotherapy.
  • The median (mean, range) age at the time of local recurrence was 57.9 (57.4, 28.9-71.7) years, and the median interval from primary surgery 2.22 (3.88, 0.27-14.46) years.
  • RESULTS: Two patients were deemed inoperable because of direct invasion of the great vessels and the liver by tumour.
  • The remaining 14 patients had recurrence in residual adrenal tissue (two), para-aortic nodes (three), para-caval nodes (two), retrocaval nodes (one), renal bed (six), liver, spleen and stomach (one each), and diaphragm (two).
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Kidney Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Nephrectomy / methods
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15705072.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


88. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB: Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol; 2005 Jan 1;23(1):133-41
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.
  • PURPOSE: The Cytokine Working Group conducted a randomized phase III trial to determine the value of outpatient interleukin-2 (IL-2) and interferon alfa-2b (IFN) relative to high-dose (HD) IL-2 in patients with metastatic renal cell carcinoma.
  • PATIENTS AND METHODS: Patients were stratified for bone and liver metastases, primary tumor in place, and Eastern Cooperative Oncology Group performance status 0 or 1 and then randomly assigned to receive either IL-2 (5 MIU/m(2) subcutaneously every 8 hours for three doses on day 1, then daily 5 days/wk for 4 weeks) and IFN (5 MIU/m(2) subcutaneously three times per week for 4 weeks) every 6 weeks or HD IL-2 (600,000 U/kg/dose intravenously every 8 hours on days 1 through 5 and 15 to 19 [maximum 28 doses]) every 12 weeks.
  • For patients with bone or liver metastases (P = .001) or a primary tumor in place (P = .040), survival was superior with HD IL-2.
  • CONCLUSION: This randomized phase III trial provides additional evidence that HD IL-2 should remain the preferred therapy for selected patients with metastatic renal cell carcinoma.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Renal Cell / drug therapy. Interferon-alpha / administration & dosage. Interleukin-2 / administration & dosage. Kidney Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Injections, Subcutaneous. Male. Middle Aged. Neoplasm Metastasis. Recombinant Proteins. Survival Rate

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Sep 1;23(25):6267-8; author reply 6268-9 [16135500.001]
  • [CommentIn] J Clin Oncol. 2005 Sep 20;23(27):6797-8; author reply 6798-9 [16170190.001]
  • [ErratumIn] J Clin Oncol. 2005 Apr 20;23(12):2877
  • (PMID = 15625368.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Interleukin-2; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


89. Alvarez-Múgica M, Bulnes Vázquez V, Jalón Monzón A, Gil A, Rodríguez Robles L, Miranda Aranzubía O: Late recurrence from a renal cell carcinoma: solitary right maxilar mass 17 years after surgery. Arch Esp Urol; 2010 Mar;63(2):147-50
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late recurrence from a renal cell carcinoma: solitary right maxilar mass 17 years after surgery.
  • OBJECTIVES: To report a new case of late renal cell carcinoma recurrence.
  • METHODS: Renal cell carcinoma represents approximately 3% of all adult malignancies.
  • The most frequent metastatic sites are lung (76%), regional lymph nodes (66%), bone (42%), and liver (41%), and it is the third most common infraclavicular neoplasm to metastasize to head and neck.
  • The histological diagnosis of the referred mass was clear cell carcinoma.
  • Examination under general anaesthesia and biopsy was performed revealing metastasis of a renal cell carcinoma.
  • CONCLUSIONS: The natural history of renal cell carcinoma is highly variable, metastases may present decades after the removal of the primary disease, however, only 1% of patients with renal cell carcinoma have metastases confined only to the head and neck, and solitary cervical metastatic mass is rare.
  • Moreover, renal cell carcinoma should be considered in the differential diagnosis of any growing lesion in the head and neck.
  • [MeSH-major] Carcinoma, Renal Cell / diagnosis. Carcinoma, Renal Cell / surgery. Kidney Neoplasms / surgery. Maxillary Neoplasms / diagnosis. Neoplasms, Second Primary / diagnosis

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20378937.001).
  • [ISSN] 1576-8260
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


90. Ersoy O: Very high alpha-fetoprotein in a young man due to concomitant presentation of hepatocellular carcinoma and Sertoli cell testis tumor. World J Gastroenterol; 2005 Nov 28;11(44):7051-3
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Very high alpha-fetoprotein in a young man due to concomitant presentation of hepatocellular carcinoma and Sertoli cell testis tumor.
  • Studies reported that there is a close relationship between hepatocellular carcinoma (HCC) and testis carcinoma.
  • Like HCC, germ cell tumors of the testis also release AFP; but it is shown that some of Sertoli cell tumors of testis can also release AFP( [10] ).
  • [MeSH-major] Liver Neoplasms. Sertoli Cell Tumor. Testicular Neoplasms. alpha-Fetoproteins / metabolism
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. Carcinoma, Hepatocellular / blood. Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / pathology. Comorbidity. Humans. Male. Neoplasms, Multiple Primary

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437617.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins
  • [Other-IDs] NLM/ PMC4717055
  •  go-up   go-down


91. Qian HL, Peng XX, Chen SH, Ye HM, Qiu JH: p62 Expression in primary carcinomas of the digestive system. World J Gastroenterol; 2005 Mar 28;11(12):1788-92
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p62 Expression in primary carcinomas of the digestive system.
  • AIM: To characterize p62 expression and define the relationship between p62 expression and cell proliferation in primary carcinomas of the digestive system.
  • METHODS: p62 expression was characterized in surgically resected tumor specimens from 60 patients with primary carcinomas of the digestive tract (including 22 esophageal carcinomas, 17 gastric carcinomas, and 21 colorectal carcinomas) and 40 patients with hepatocellular carcinoma (HCC) by immunohistochemistry (IHC).
  • The cell proliferation was determined by IHC of Ki-67 in 40 patients with HCC.
  • RESULTS: Twenty-two cases of esophageal carcinoma were histopathologically diagnosed as squamous cell carcinoma.
  • p62 expression in primary carcinomas of the gastrointestinal tract (60/60,100%) was higher than that (27/40, 67.5%) of HCC (P<0.01, chi(2) = 19.63).
  • CONCLUSION: p62 expression is common in carcinomas of the digestive system and higher in carcinomas of the gastrointestinal tract than in primary HCC. p62 is a cellular differentiation-related protein.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Digestive System Neoplasms / metabolism. Liver Neoplasms / metabolism. RNA-Binding Proteins / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Cell Division. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Esophageal Neoplasms / metabolism. Esophageal Neoplasms / pathology. Humans. Immunohistochemistry. Middle Aged. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15793865.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / P62 protein, human; 0 / RNA-Binding Proteins
  • [Other-IDs] NLM/ PMC4305875
  •  go-up   go-down


92. Dong-Dong L: Up-regulation expression of MLC1 in human liver cancer tissue and enhanced SMMC7721 cell tumorigenesis in vivo and vitro. Hepatogastroenterology; 2005 Jul-Aug;52(64):1186-90
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Up-regulation expression of MLC1 in human liver cancer tissue and enhanced SMMC7721 cell tumorigenesis in vivo and vitro.
  • BACKGROUND/AIMS: We screened a novel gene MLC1 in human liver cancer tissue by differential display, and its cDNA full-length is 1600bp.
  • The purpose of this study is to find expression of MLC1 gene in human liver cancer tissue and the affect to SMMC7721 cell tumorigenesis in vivo and vitro.
  • METHODOLOGY: 250 cases of primary HCC tissue samples were studied for MLC1 mRNA and protein expression using RT-PCR, western blot, immunohistochemistry, MLC1 stable transfection into SMMC771, and SMMC7721 cells growth curve was analyzed by MTT method and SMMC7721 cells tumorigenesis in vivo.
  • CONCLUSIONS: MLC1 gene showed up-regulation expression at both the mRNA and protein levels in HCC tissues and that MLC1 plays an important role in the growth of hepatoma cell SMMC7721 in vitro and vivo.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / etiology. Liver Neoplasms / metabolism. Membrane Proteins / metabolism
  • [MeSH-minor] Adult. Animals. Cell Culture Techniques. Cell Line, Tumor. Female. Humans. Male. Mice. Mice, Inbred BALB C. Middle Aged. RNA, Messenger / metabolism. Transfection. Up-Regulation

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16001658.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / MLC1 protein, human; 0 / Membrane Proteins; 0 / Mlc1 protein, mouse; 0 / RNA, Messenger
  •  go-up   go-down


93. Chan KY, Lai PB, Squire JA, Beheshti B, Wong NL, Sy SM, Wong N: Positional expression profiling indicates candidate genes in deletion hotspots of hepatocellular carcinoma. Mod Pathol; 2006 Dec;19(12):1546-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positional expression profiling indicates candidate genes in deletion hotspots of hepatocellular carcinoma.
  • Molecular characterizations of hepatocellular carcinoma have indicated frequent allelic losses on chromosomes 4q, 8p, 16q and 17p, where the minimal deleted regions have been further defined on 4q12-q23, 4q31-q35, 8p21-p22, 16q12.1-q23.1 and 17p13.
  • Despite these regions are now well-recognized in early liver carcinogenesis, few underlying candidate genes have been identified.
  • In an effort to define affected genes within common deleted loci of hepatocellular carcinoma, we conducted transcriptional mapping by high-resolution cDNA microarray analysis.
  • In 20 hepatocellular carcinoma cell lines and 20 primary tumors studied, consistent downregulations of novel transcripts were highlighted throughout the entire genome and within sites of frequent losses.
  • In primary hepatocellular carcinoma examined, a significant repression of MT1G by more than 100-fold was indicated in 63% of tumors compared to the adjacent nonmalignant liver (P = 0.0001).
  • In summary, transcriptional mapping by microarray indicated a number of previously undescribed downregulated genes in hepatocellular carcinoma, and highlighted potential candidates within common deleted regions.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Gene Deletion. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Liver Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Cell Line, Tumor. Down-Regulation. Female. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis


94. Zhang M, Li B, Yan LN, Yin F, Wen TF, Zeng Y, Zhao JC, Ma YK: Development of a survival evaluation model for liver transplant recipients with hepatocellular carcinoma secondary to hepatitis B. World J Gastroenterol; 2008 Feb 28;14(8):1280-5
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of a survival evaluation model for liver transplant recipients with hepatocellular carcinoma secondary to hepatitis B.
  • AIM: To develop a model using easily obtainable, objective, verifiable preoperative parameters, to help evaluate post transplant survival probability for hepatocellular carcinoma (HCC) patients with hepatitis B.
  • METHODS: We retrospectively examined a cohort of 150 consecutive primary cadaveric liver transplants with HCC in our center over 6 years.
  • The predictive power of a new model and the model for end stage liver disease was compared by the receiver operating characteristic curve.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Carcinoma, Hepatocellular / therapy. Hepatitis B / complications. Hepatitis B / therapy. Liver Neoplasms / etiology. Liver Neoplasms / therapy. Liver Transplantation / methods
  • [MeSH-minor] Adult. Aged. Cell Survival. Cohort Studies. Female. Humans. Liver Diseases / diagnosis. Liver Diseases / therapy. Male. Middle Aged. Proportional Hazards Models. Retrospective Studies

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Liver Transpl. 2004 Jan;10(1):7-15 [14755772.001]
  • [Cites] Hepatology. 2007 Feb;45(2):269-76 [17256759.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Apr;130(4):187-96 [14685850.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Apr;130(4):197-202 [14770307.001]
  • [Cites] Hepatogastroenterology. 2004 Mar-Apr;51(56):510-4 [15086193.001]
  • [Cites] J Hepatol. 2004 Jun;40(6):897-903 [15158328.001]
  • [Cites] Hepatology. 2000 Apr;31(4):864-71 [10733541.001]
  • [Cites] J Am Coll Surg. 2000 Oct;191(4):389-94 [11030244.001]
  • [Cites] Hepatology. 2001 Feb;33(2):464-70 [11172350.001]
  • [Cites] Hepatology. 2001 May;33(5):1080-6 [11343235.001]
  • [Cites] Liver Transpl. 2001 Jul;7(7):567-80 [11460223.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • [Cites] Liver Transpl. 2002 Mar;8(3):278-84 [11910574.001]
  • [Cites] Liver Transpl. 2002 Apr;8(4):323-8 [11965574.001]
  • [Cites] Gastroenterology. 2003 Jan;124(1):91-6 [12512033.001]
  • [Cites] Liver Transpl. 2003 Feb;9(2):117-23 [12548503.001]
  • [Cites] J Am Coll Surg. 2003 Jun;196(6):887-97 [12788425.001]
  • [Cites] Transplantation. 2004 Jan 15;77(1):99-106 [14724442.001]
  • [Cites] Transplantation. 2002 Jul 27;74(2):173-81 [12151728.001]
  • [Cites] Liver Transpl. 2002 Sep;8(9):851-8 [12200791.001]
  • [Cites] Liver Transpl. 2002 Oct;8(10):873-83 [12360427.001]
  • [Cites] Liver Transpl. 2004 Jul;10(7):903-7 [15237375.001]
  • [Cites] Am J Transplant. 2004 Oct;4(10):1643-9 [15367219.001]
  • [Cites] Hepatology. 2004 Oct;40(4):787-9 [15382164.001]
  • [Cites] Hepatology. 2004 Oct;40(4):802-10 [15382176.001]
  • [Cites] Liver Transpl. 2004 Oct;10(10 Suppl 2):S4-9 [15382217.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S261-7 [15508092.001]
  • [Cites] N Engl J Med. 1971 Feb 25;284(8):416-24 [4395661.001]
  • [Cites] Radiology. 1982 Apr;143(1):29-36 [7063747.001]
  • [Cites] Radiology. 1983 Sep;148(3):839-43 [6878708.001]
  • [Cites] J Pediatr. 1987 Oct;111(4):479-89 [3309232.001]
  • [Cites] J Gastroenterol Hepatol. 1995 Jan-Feb;10(1):47-50 [7620107.001]
  • [Cites] Semin Liver Dis. 1999;19(3):311-22 [10518310.001]
  • [Cites] Hepatology. 2005 Jan;41(1):32-9 [15690479.001]
  • [Cites] Gut. 2005 Jun;54(6):843-51 [15888795.001]
  • [Cites] Hepatology. 2004 Mar;39(3):764-9 [14999695.001]
  • (PMID = 18300358.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2690680
  •  go-up   go-down


95. Mudali SV, Fu B, Lakkur SS, Luo M, Embuscado EE, Iacobuzio-Donahue CA: Patterns of EphA2 protein expression in primary and metastatic pancreatic carcinoma and correlation with genetic status. Clin Exp Metastasis; 2006;23(7-8):357-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of EphA2 protein expression in primary and metastatic pancreatic carcinoma and correlation with genetic status.
  • EphA2 is a transmembrane receptor tyrosine kinase that functions in the regulation of cell growth, survival, angiogenesis, and migration and EphA2 targeting has been proposed as a novel therapeutic strategy for neoplasms that overexpress this protein.
  • EphA2 overexpression has been correlated with increased invasive and metastatic ability in pancreatic cancer cell lines.
  • We collected clinicopathologic data and paraffin-embedded materials from 98 patients with primary and/or metastatic pancreatic cancer and performed immunohistochemical labeling for EphA2 protein.
  • When evaluated specifically for labeling intensity, primary and metastatic carcinomas were more strongly positive compared to benign ducts and PanIN lesions (P < 0.00001 and P < 0.01, respectively) and poorly differentiated carcinomas were more strongly positive for EphA2 than well and moderately differentiated tumors (P < 0.005).
  • When primary carcinomas without metastatic disease were specifically compared to carcinomas with associated metastatic disease, the advanced carcinomas showed relatively less strong positive labeling for EphA2 (P < 0.008).
  • Moreover, decreased EphA2 labeling was more commonly found in liver (P < 0.002), lung (P < 0.004) or peritoneal metastases (P < 0.01) as compared to distant lymph node metastases (P < 0.01).

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol. 1997 Oct;273(4 Pt 1):G824-32 [9357823.001]
  • [Cites] Cell Growth Differ. 1999 Sep;10(9):629-38 [10511313.001]
  • [Cites] Cancer Gene Ther. 2004 Nov;11(11):757-66 [15359289.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):226-31 [15671550.001]
  • [Cites] Oncogene. 2005 Apr 14;24(16):2684-94 [15829979.001]
  • [Cites] Anticancer Res. 2005 Jul-Aug;25(4):2943-50 [16080548.001]
  • [Cites] Cancer Biol Ther. 2005 May;4(5):548-54 [15846069.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Oct 1;162(1):63-7 [16157202.001]
  • [Cites] J Biol Chem. 2005 Oct 7;280(40):34008-18 [16051609.001]
  • [Cites] Neoplasia. 2005 Aug;7(8):717-22 [16207473.001]
  • [Cites] Gynecol Oncol. 2005 Nov;99(2):278-86 [16061279.001]
  • [Cites] Adv Surg. 2005;39:223-44 [16250554.001]
  • [Cites] Mol Cancer Res. 2005 Oct;3(10):541-51 [16254188.001]
  • [Cites] FASEB J. 2005 Nov;19(13):1884-6 [16166198.001]
  • [Cites] Oncogene. 2005 Nov 24;24(53):7859-68 [16103880.001]
  • [Cites] J Biol Chem. 2005 Dec 23;280(51):42375-82 [16236711.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):353-60 [16428472.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Oncogene. 2000 Nov 20;19(49):5614-9 [11114742.001]
  • [Cites] Oncol Rep. 2001 Jan-Feb;8(1):89-92 [11115575.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1833-8 [11280733.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2301-6 [11280802.001]
  • [Cites] Virchows Arch. 2001 Dec;439(6):798-802 [11787853.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):819-26 [11830538.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2840-7 [12019162.001]
  • [Cites] J Biol Chem. 2002 Oct 18;277(42):39274-9 [12167657.001]
  • [Cites] Oncogene. 2002 Oct 31;21(50):7690-9 [12400011.001]
  • [Cites] Mol Cancer Res. 2002 Nov;1(1):79-87 [12496371.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):613-8 [12576426.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1037-42 [12651595.001]
  • [Cites] Science. 2003 May 9;300(5621):949 [12738854.001]
  • [Cites] Oncol Rep. 2004 Mar;11(3):605-11 [14767510.001]
  • [Cites] Oncogene. 2004 Feb 19;23(7):1448-56 [14973554.001]
  • [Cites] Clin Chem. 2004 Mar;50(3):490-9 [14726470.001]
  • [Cites] Am J Clin Pathol. 2004 Feb;121(2):226-30 [14983936.001]
  • [Cites] J Cell Sci. 2004 Apr 15;117(Pt 10):2037-49 [15054110.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Aug 6;320(4):1096-102 [15249202.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5145-50 [15297418.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):312-9 [15297167.001]
  • [Cites] Nat Genet. 2004 Sep;36(9):979-83 [15300251.001]
  • [Cites] Mol Cell Biol. 1990 Dec;10(12):6316-24 [2174105.001]
  • [Cites] Cancer. 1992 Apr 1;69(7):1674-81 [1551052.001]
  • [Cites] Science. 1994 Nov 4;266(5186):816-9 [7973638.001]
  • [Cites] Science. 1995 Apr 28;268(5210):567-9 [7536959.001]
  • [Cites] Cancer Res. 1995 Jun 1;55(11):2394-9 [7757992.001]
  • (PMID = 17146615.001).
  • [ISSN] 0262-0898
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA106610-04; United States / NCI NIH HHS / CA / P50 CA062924; United States / NCI NIH HHS / CA / CA62924; United States / NCI NIH HHS / CA / K08 CA106610-04; United States / NCI NIH HHS / CA / CA106610; United States / NCI NIH HHS / CA / K08 CA106610
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, EphA2
  • [Other-IDs] NLM/ NIHMS147177; NLM/ PMC2755224
  •  go-up   go-down


96. Bodendorf MO, Haas V, Laberke HG, Blumenstock G, Wex P, Graeter T: Prognostic value and therapeutic consequences of vascular invasion in non-small cell lung carcinoma. Lung Cancer; 2009 Apr;64(1):71-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value and therapeutic consequences of vascular invasion in non-small cell lung carcinoma.
  • The prognostic relevance of blood vessel invasion (BVI) in non-small cell lung carcinoma (NSCLC) remains controversial, as is the question of whether its finding should influence therapeutic decisions after an R0 resection.
  • All had been treated by potentially curative surgical resection of the primary tumor and systematic lymphadenectomy.
  • Thus 31.2% of the patients developed distant metastases by hematogenous spread (to the brain, bones, lung, adrenal, and liver, in descending order of frequency), mostly within two years of surgery.
  • Adenocarcinomas showed a strong tendency to be associated with a poorer prognosis than squamous cell carcinomas, probably because of their more frequent involvement of blood vessels.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / pathology. Neoplastic Cells, Circulating / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pneumonectomy. Prognosis. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18790545.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


97. Silva EG, Deavers MT, Bodurka DC, Malpica A: Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma? Int J Gynecol Pathol; 2006 Jan;25(1):52-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma?
  • The association of this type of tumor with undifferentiated carcinoma is rare.
  • The endometrioid carcinoma involved the endometrium in 14 cases, the endometrium and 1 or both ovaries in 9 cases, and the ovaries in 2 cases.
  • Undifferentiated carcinoma associated with low-grade endometrioid carcinoma was found at presentation in 19 grade 1 or 2 endometrioid carcinomas: 15 in the endometrium and 5 in the ovary.
  • In one of these cases, undifferentiated carcinoma was found in the endometrium and the ovary.
  • Undifferentiated carcinoma was found after resection of low-grade endometrioid carcinoma in six cases, involving the retroperitoneum, pelvis, vagina, or liver.
  • The undifferentiated carcinoma was composed exclusively of diffuse sheets and solid nests of epithelial cells in l0 cases.
  • Foci of undifferentiated carcinoma may be confused with solid endometrioid adenocarcinoma erroneously leading to the diagnosis of a grade 3 or a significantly less aggressive grade 2 endometrioid carcinoma.
  • The recognition of undifferentiated carcinoma in an otherwise low-grade endometrioid adenocarcinoma is extremely important because it indicates aggressive behavior.
  • In asynchronous cases, being aware of this association can explain the absence of a second primary.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Cell Transformation, Neoplastic. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Recurrence, Local. Neoplasms, Second Primary

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int J Gynecol Pathol. 2006 Jul;25(3):304
  • (PMID = 16306785.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


98. Radfar L, Fatahzadeh M: Neuroendocrine carcinoma of the oral cavity: a case report and review of the literature. Gen Dent; 2008 Nov-Dec;56(7):714-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine carcinoma of the oral cavity: a case report and review of the literature.
  • Neuroendocrine (NE) carcinoma is a rare disease originating from the NE cell system, which is considered to be the third division of the nervous system.
  • Based on their biological characteristics, NE carcinomas are classified into three subtypes: well-differentiated NE carcinoma (typical carcinoid tumor), moderately differentiated NE carcinoma (atypical carcinoid tumor), and poorly differentiated carcinoma (small cell carcinoma).
  • Among the primary tumors, the propensity for disease to spread to the oral region varies.
  • This case report describes a patient with an unknown primary NE malignancy that led to metastatic lesions in both the liver and mandibular soft tissues.
  • [MeSH-major] Carcinoma, Neuroendocrine / secondary. Mandibular Neoplasms / secondary. Neoplasms, Unknown Primary
  • [MeSH-minor] Adult. Brain Neoplasms / secondary. Fatal Outcome. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis / pathology. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19014033.001).
  • [ISSN] 0363-6771
  • [Journal-full-title] General dentistry
  • [ISO-abbreviation] Gen Dent
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down


99. El-Bassiouny AE, Zoheiry MM, Nosseir MM, El-Ahwany EG, Ibrahim RA, El-Bassiouni NE: Expression of cyclooxygenase-2 and transforming growth factor-beta1 in HCV-induced chronic liver disease and hepatocellular carcinoma. MedGenMed; 2007;9(3):45
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cyclooxygenase-2 and transforming growth factor-beta1 in HCV-induced chronic liver disease and hepatocellular carcinoma.
  • Cyclooxygenase-2 (COX-2) and transforming growth factor-beta1 (TGF-beta1) were modulated in a variety of viral infections, but there is a paucity of data about their role in the pathologic process of cirrhosis and/or hepatocellular carcinoma (HCC) following chronic hepatitis C virus (HCV) infection.
  • Fifteen wedge liver biopsies, taken during laparoscopic cholecystectomy, were included in the study as normal controls.
  • Immunohistochemistry using primary antibodies against both factors revealed weak to faint immunoreactivity to COX-2 and TGF-beta1 in normal hepatic tissue (< 30% and < 50% of the cells, respectively).
  • CONCLUSION: These findings may suggest that TGF-beta1 plays a role in hepatic cell damage following HCV infection thus stressing the usefulness of this cytokine as a prognostic marker for liver cell injury.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Cyclooxygenase 2 / biosynthesis. Hepatitis C, Chronic / metabolism. Liver Cirrhosis / metabolism. Liver Neoplasms / metabolism. Transforming Growth Factor beta1 / biosynthesis
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 2000 Mar;16(3):599-610 [10675495.001]
  • [Cites] Biochem J. 2006 Sep 15;398(3):371-80 [16800815.001]
  • [Cites] Am J Pathol. 2000 Jul;157(1):29-35 [10880372.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1410-8 [11350912.001]
  • [Cites] Nat Genet. 2001 Oct;29(2):117-29 [11586292.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1475-83 [11745225.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):366-75 [11832451.001]
  • [Cites] Front Biosci. 2002 Apr 1;7:d793-807 [11897555.001]
  • [Cites] Anticancer Drugs. 2002 Feb;13(2):127-37 [11901304.001]
  • [Cites] J Lab Clin Med. 2002 Apr;139(4):234-43 [12024111.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Oct;17(10):1110-6 [12201873.001]
  • [Cites] Hepatology. 2002 Oct;36(4 Pt 1):885-94 [12297835.001]
  • [Cites] World J Gastroenterol. 2002 Oct;8(5):815-7 [12378621.001]
  • [Cites] J Clin Invest. 2002 Dec;110(12):1831-8 [12488433.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1566-72 [12684433.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8621-3 [12861075.001]
  • [Cites] Viral Immunol. 2003;16(4):447-60 [14733733.001]
  • [Cites] Mod Pathol. 2004 Oct;17(10):1169-79 [15218507.001]
  • [Cites] Gut. 2004 Nov;53(11):1665-72 [15479690.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7384-8 [1380156.001]
  • [Cites] Cancer. 1992 Sep 15;70(6):1488-92 [1325272.001]
  • [Cites] Rev Gastroenterol Mex. 1994 Jan-Mar;59(1):17-22 [8209148.001]
  • [Cites] Radiology. 1994 Aug;192(2):379-87 [8029401.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1452-7 [7882352.001]
  • [Cites] Gastroenterology. 1995 Jul;109(1):285-301 [7797026.001]
  • [Cites] J Clin Invest. 1995 Jul;96(1):491-503 [7615821.001]
  • [Cites] J Hepatol. 1995 Jun;22(6):696-9 [7560864.001]
  • [Cites] East Afr Med J. 1995 Sep;72(9):584-7 [7498046.001]
  • [Cites] Hepatology. 1996 Jun;23(6):1384-92 [8675155.001]
  • [Cites] Nihon Rinsho. 1996 Jun;54(6):1499-504 [8691600.001]
  • [Cites] Br J Pharmacol. 1997 Mar;120(5):910-6 [9138698.001]
  • [Cites] FASEB J. 1998 Sep;12(12):1063-73 [9737710.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 1999 Apr;28(4):386-92 [10204502.001]
  • [Cites] Gut. 2005 Jan;54(1):134-41 [15591519.001]
  • [Cites] J Virol. 2005 Aug;79(15):9725-34 [16014934.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2202-9 [16489022.001]
  • [Cites] J Biol Chem. 2006 Mar 17;281(11):7468-78 [16407286.001]
  • [Cites] Cytokine Growth Factor Rev. 2000 Mar-Jun;11(1-2):159-68 [10708963.001]
  • (PMID = 18092051.001).
  • [ISSN] 1531-0132
  • [Journal-full-title] MedGenMed : Medscape general medicine
  • [ISO-abbreviation] MedGenMed
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Transforming Growth Factor beta1; EC 1.14.99.1 / Cyclooxygenase 2
  • [Other-IDs] NLM/ PMC2100111
  •  go-up   go-down


100. Leibovich BC, Cheville JC, Lohse CM, Zincke H, Frank I, Kwon ED, Merchan JR, Blute ML: A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol; 2005 Nov;174(5):1759-63; discussion 1763
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.
  • PURPOSE: We developed a clinically useful scoring algorithm to predict cancer specific survival for patients with clear cell metastatic renal cell carcinoma (RCC).
  • MATERIALS AND METHODS: We studied 727 patients treated with radical nephrectomy for clear cell RCC from 1970 to 2000 who had distant metastases at nephrectomy (285) or in whom metastases subsequently developed (442).
  • RESULTS: There were 606 deaths from clear cell RCC at a median of 1.0 years (range 0 to 14) following metastatic RCC.
  • Constitutional symptoms at nephrectomy (+2), metastases to the bone (+2) or liver (+4), metastases in multiple simultaneous sites (+2), metastases at nephrectomy (+1) or within 2 years of nephrectomy (+3), complete resection of all metastatic sites (-5), tumor thrombus level I to IV (+3), and the primary pathological features of nuclear grade 4 (+3) and histological tumor necrosis (+2) were significantly associated with death from RCC.
  • CONCLUSIONS: This scoring algorithm can be used to predict cancer specific survival for patients with metastatic clear cell RCC.
  • [MeSH-major] Adenocarcinoma, Clear Cell / mortality. Algorithms. Carcinoma, Renal Cell / mortality. Cause of Death. Kidney Neoplasms / mortality
  • [MeSH-minor] Adult. Age Distribution. Aged. Clinical Trials as Topic. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Nephrectomy / methods. Predictive Value of Tests. Probability. Prognosis. Prospective Studies. Registries. Retrospective Studies. Risk Assessment. Sex Distribution. Survival Analysis






Advertisement